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Despite the availability of powerful immunosuppressive agents, rejection 
of the allografted heart remains one of the major problems associated with 
cardiac transplantation. The inflammatory process in response to alloantigen is 
in part due to the production by different cell types of soluble endogenous 
mediators, including both cytokines and granzymes. The studies contained 
within this dissertation were designed to further understand the 
pathophysiological mechanisms involved in cardiac allograft rejection by 
examining the production of these cytotoxic mediators. Specifically, detection 
and quantitation of the cytotoxic products tumor necrosis factor-a (TNFa) and-~ 
(lymphotoxin, (LT)), and the T cell proteases, granzymes A and B (Hanukkah 
Factor (HF) and Cl1, respectively), were measured during the process of rat 
cardiac allograft rejection. Determination of which cytotoxic cytokine products 
are present post-tranplantation and when during the time course of rejection, 
may lead to more effective therapies aimed at promoting graft success. 
Furthermore, the achievement of successful cardiac transplantation is, in 
fact, critically dependent on immunosuppressive agents that can effectively 
prolong graft survival and prevent allograft rejection. The current protocol of 
administering potent immunosuppressive drugs to transplant recipients 
dramatically increases the chances of graft survival, accompanied frequently, 
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however, by toxic side effects. One approach to alleviating adverse side effects 
associated with high dose immunosuppression employs the administration of a 
combination of low dose immunosuppressive agents that may act additively or 
synergistically to inhibit alloactivation. Studies in this dissertation were 
designed to examine the use of a low dose cyclosporine A (CSA)/methothrexate 
(MTX) combination therapy following cardiac transplantation. Specifically, the 
ability of low dose CSA/MTX combination treatment to prolong cardiac allograft 
survival was determined. Additionally, the expression of cytotoxic genes, TNFa, 
LT, HF, and C11, in the transplanted cardiac grafts was measured in combination 
CSA/MTX-treated recipients. Studies such as these may provide opportunities 
to promote graft survival by using combination therapies which may minimize 
adverse side effects. 
Historical Background 
The first half of the twentieth century was characterized by a debate 
between proponents of pure cellular participation and proponents of the 
antibody and complement system as agonists in graft rejection. In the early 1940s 
the cellular nature of the alloimmune response was reported, and the allogeneic 
rejection reaction was largely attributed to cellular immune responses (Gibson & 
Medawar, 1943; Medawar et al., 1944). By the mid 1950s, the transplant rejection 
response was characterized as the result of cell-mediated (Billingham et al., 1954) 
and antigen-specific (Gorer, 1938) events. Despite the fact that the allograft 
rejection response has been shown to be a result of antigen-specific cellular 
mechanisms, the pathophysiological events which lead to the destruction of 
foreign donor tissue have yet to be elucidated. There are a number of 
mechanisms which have been proposed as effectors of graft rejection, including 
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cytotoxic alloantibodies (Carpenter et al., 1976), delayed-type hypersensitivity 
(Loveland & McKenzie, 1982), cytotoxic T cells (Lowry et al., 1985a; Hall et al., 
1978), natural killer (NK) cells (Strom et al., 1977), and macrophages (MacPherson 
& Christmas, 1984). It is not known, however, to what extent each of these 
effectors may contribute to rejection of the transplanted graft. Therefore, it is 
clear that a more detailed examination of discrete cellular mechanisms and 
subpopulations involved in graft rejection needs to be performed. 
Mechanisms of Allograft Rejection 
Role of Genetics and the MHC 
Although the immunological basis for transplant rejection has been well 
established, the detailed cellular mechanisms responsible for the destruction of 
donor tissue by the host's immune system are not yet fully understood. Early 
studies have indicated that grafts which were transplanted between genetically 
identical individuals or isografts were accepted, whereas grafts transplanted 
between genetically non-identical individuals or allografts were rejected (Little & 
Tyzzer, 1916). In fact, it has been demonstrated that successful transplantation 
depends on the donor and recipient sharing a number of independently 
segregating alleles, known as the histocompatibility genes (Gorer et al., 1948). 
Genetic studies on the segregation of histocompatibility genes have shown a 
large number of independently segregating loci in all vertebrate species. 
However, there is one gene region or cluster, the major histocompatibility 
complex (MHC), also referred to in humans as the human leukocyte antigen 
complex (or HLA), which elicits stronger allogeneic reactions than the others 
(Dausset et al., 1965; Hart & Fabre, 1981). The MHC maps to a single 
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chromosome, located on the short arm of chromosome 6 in humans (Robinson 
1989), and encodes four classes of genes, the first two of which provide the major 
antigenic stimulus in allograft rejection. MHC class I products are constitutively 
expressed in humans by most tissues and cells except erythrocytes. Class II 
products are much more limited in distribution and are normally expressed on B 
lymphocytes, dendritic cells, monocytes and macrophages, as well as most 
endothelia, but may be induced on other cell types by gamma interferon (IFNy) 
(Fuggle et al., 1986). 
The MHC products, which are commonly referred to as the MHC 
antigens, consist of heterodimeric cell surface molecules that are highly 
polymorphic. MHC is essential for reactions involving the immune response 
because they are responsible for antigen presentation and self-recognition 
(Benacerraf, 1981). Although non-MHC antigens may contribute to graft 
rejection (Witherspoon & Storb, 1989), the strongest rejection responses appear to 
be directed against the products of the MHC, specifically class I and class II 
antigens (Dausset et al., 1965; Hart & Fabre, 1981). In fact, the immune system is 
commonly referred to as being "MHC-restricted" (Zinkernagel & Doherty, 1974). 
Mature T cells express receptors (TCR) that recognize foreign antigens 
which are generally in the form of short peptides bound to self MHC molecules 
(Jorgenen et al., 1992) (Figure lA). In normal host defense mechanisms, 
exogenous antigens are presented in the context of Class II, whereas 
intracellularly derived antigens such as viral proteins are processed and 
presented in association with MHC class I. The transplantation of MHC-
mismatched tissue presents an interesting variation in T cell recognition of 
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antigen because the foreign antigens themselves are MHC molecules. Initiation 
of allograft rejection is thought to involve recognition of donor allogeneic MHC 
antigens expressed on the allograft and/ or on "passenger leukocytes" within the 
graft, by receptors of CD4 + /T helper cells of the recipient. Activated CD4 + T 
cells, along with antigen presenting cells, produce cytokines that support 
lymphocyte proliferation and maturation of CDS+ cytotoxic T cells which are 
specific for donor class I MHC. Infiltrating T cells may recognize processed 
endogenous peptides in the context of self MHC (Figure lC), or processed 
allogeneic MHC antigens presented in association with self-MHC (Figure 1D). 
Additionally, direct recognition of epitopes on native alloantigen can also occur 
(Figure lB). Support for these mechanisms of T cell recognition of alloantigen 
exists, but is not discussed here (Reviewed in Krensky et al., 1990). 
Cells Mediating Allograft Rejection 
The host cells infiltrating into acutely rejecting tissues include T and B 
lymphocytes, macrophages, and NK cells (Tilney 1975 and Mason 1986). 
Progressive infiltration of allografted tissues by host mononuclear cells is 
characteristic of the rejection process. Following transplantation, host 
lymphocytes infiltrate perivascular areas and subsequently scatter throughout 
the graft parenchyma. As inflammatory reactions proceed, macrophages become 
increasingly prevalent, with disruption of peri-capillary tissues, progressive 
interstitial inflammation, and eventual tissue necrosis. At the same time, both 
mature and blastic lymphocytes increase within recipient lymphoid 






Fig. 1. Possible mechanisms of T cell recognition of alloantigen. T cell receptors 
(TCR) typically recognize foreign antigens in the form of short processed 
peptides bound to self MHC (A). However, during transplantation of an 
allograft, infiltrating T cells may recognize allogeneic MHC antigens as foreign 
(B), TCR may recognize self-peptides in the context of allogeneic MHC located on 
the allograft or passenger leukocytes (C), or processed allogeneic MHC peptides 
may also be recognized by the TCR when presented in association with self-
MHC (D). 
T-Cell Activation and Proliferation 
As mentioned earlier, the early T cell response to alloantigen is primarily 
by the CD4+ /T helper cells that detect foreign MHC class II antigens on the 
allografted tissue. It has also been shown, however, that much of the initial 
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immunogenicity of the transplanted graft may be a response by the recipient T 
cells against passenger leukocytes, which are dendritic leukocytes within the 
graft that express high levels of MHC class II antigen (Larsen, et al., 1990). Once 
recognition of foreign or allogeneic antigen occurs, transmembrane signals lead 
to intracellular activation and subsequent expansion and differentiation of the 
recipient's T lymphocytes. Early intracellular events in this process include the 
phosphophatidylinositol and the tyrosine kinase pathways, which act as second 
messengers during T cell activation. 
In the phosphophatidylinositol pathway, activation of intracellular 
phospholipase C cleaves phosphatidylinositol 4, 5-biphosphate (PIP2) into two 
potent second messengers, inositol 1, 4, 15-triphosphate and diacyl glycerol, 
which results in a 10-fold increase in intracellular calcium levels and activation of 
protein kinase C, respectively (Krensky et al., 1990). Calcium-activated kinases, 
in turn, modify DNA binding proteins, thereby affecting gene expression (in 
particular interleukin-2 (IL-2)) and ultimately T cell activation and 
differentiation. The tyrosine kinase pathway is directly activated by membrane 
receptor recognition of foreign or allo-antigen. Tyrosine kinase phosphorylates 
phospholipase C which in turn activates PIP2, again leading to T cell activation. 
Activated CD4 + T cells, along with antigen presenting cells, produce 
cytokines that support lymphocyte proliferation and the maturation of CDS+ 
cytotoxic T cells specific for donor class I MHC. The primary responsibility of T 
cells in the acute destructive process relies on their ability to lyse donor target 
cells without the need for antibody (Hayry & Defendi, 1970). 
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Macrophage Response During Allograft Rejection 
Following TCR-antigen recognition, host macrophages are thought to 
provide the essential second signal, IL-1, which serves to trigger the proliferation 
of CD4+ T cells (Halloran et al., 1989). IL-1 also possesses many other 
proinflammatory effects, including promoting B cell growth and differentiation, 
increasing the cytotoxicity of NK cells, potentiating platelet activating factor by 
macrophages, and possessing chemotactic effects on macrophages (Halloran et 
al., 1989). In addition to IL-1, activated macrophages also have the ability to 
produce the cytokine, tumor necrosis factor alpha (TNFa). Like IL-1, TNFa 
possesses many proinflammatory effects which may contribute to the allograft 
rejection response. These effects include: potent induction of chemotactic factors 
for polymorphonuclear leukocytes and monocytes (Baggiolini et al., 1989), which 
may cause infiltration of these effector cells to the site of acute rejection, 
augmentation of class I MHC antigen expression (Tracey et al., 1987), stimulation 
of endothelium-derived platelet activating factor, which may promote ischemia 
within the graft, and induction of macrophage activation. 
In fact, the macrophage has been implicated as an effector cell in first-set 
(acute) allograft rejection (MacPherson & Christmas, 1984), and their numbers 
have been shown to dramatically increase during rejection (Leendert et al., 1992; 
Payne et al., submitted). Specifically, macrophages have been described to be the 
predominant infiltrating cell at the time of rejection and are present in intimate 
relationship to myocardial cells (Christmas & MacPherson, 1982; Forbes & 
Guttmann, 1983). Furthermore, macrophages have the ability to act both as 
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antigen presenting cells that initiate an immune response and as cytotoxic 
effector cells that contribute to graft destruction (Nathan et al., 1980). 
Other Immune Cell Populations Found in Rejecting Grafts 
In addition to T lymphocytes and macrophages, other cell populations 
infiltrate rejecting grafts. B lymphocytes, when stimulated by alloantigen, 
differentiate into antibody-producing plasma cells. B cells have been 
demonstrated to appear late during the first-set acute allograft response and are 
detected within graft infiltrates by the time rejection in complete (Payne et al., 
submitted). B cells from graft infiltrates have the ability to secrete both 
nonspecific antibodies and those directed against donor cells (Garovoy et al., 
1982). However, despite their obvious activity, their actual role in acute cell-
mediated rejection remains unknown and is not well defined. 
NK cells are a population of cytotoxic leukocytes that play a central role in 
the host defense against some malignancies. Although they infiltrate organ 
allografts rapidly, deletion experiments in graft recipients using specific anti-NK 
cell antibodies show that they are not critical in the acute rejection process 
(Heidecke et al., 1985). However, NK cells have been shown to mediate 
resistance to allogeneic and semi-allogeneic bone marrow grafts. Therefore the 
possibility exists that NK cells may effect rejection of allografts. In fact, it has 
been suggested that NK cells present at the graft site may develop into 
alloimmune cytotoxic T lymphocytes, or that NK cells may be functioning to 
promote the allograft response; perhaps by their ability to secrete lymphokines, 
such as IL-1 or IFNy, and/ or cytotoxic serine proteases (Hoffman et al., 1988). 
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Other cell types, including neutrophils and eosinophils, are present within 
the rejecting allografts, but their contribution, if any, to the rejection process is 
poorly defined. 
Effector Arms of Graft Destruction 
After placement of an allograft, a leukocyte infiltrate accumulates at the 
graft site. It is presumed that there are two principal means by which these 
infiltrating cells promote allograft rejection: either directly, through cell-
mediated injury or lysis of the graft target cells (Figure 2A), or indirectly, through 
local production of soluble mediators of the immune response (i.e., cytokines), 
which in turn lead to graft target cell death (Figure 2B). 
Fig. 2. Two examples in which infiltrating cells may mediate graft target cell 
destruction. Foreign MHC class II antigens on graft stimulate host helper T cells 
to help cytotoxic T cells to destroy graft target cells; cytotoxic T cells can also 
recognize MHC class I foreign antigens, leading to direct cell lysis of graft target 
cells (A). Helper T cells and macrophages, for example, can respond to foreign 
graft cells by producing certain soluble mediators of the immune response, or 
cytokines, which can either directly injure graft target cells themselves, or do so 
by recruiting and activating nonspecific components of graft destruction (B). 
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Direct Cell Lysis 
As mentioned earlier, activated CD4+ cells, along with antigen presenting 
cells, such as the macrophage, have the ability to produce certain cytokines that 
aid in the maturation and subsequent activation of CDS+ specific cytotoxic T 
cells. These activated cytotoxic T cells are then able to lyse foreign graft target 
cells through direct cell contact. Direct graft cell lysis is thought to result from 
the release of a preformed membrane-disrupting protein called "perforin," which 
shares structural homology to the C5b-C9 "membrane attack complex" of the 
complement cascade (Shinkai et al., 1988). The released perforin monomers bind 
to the membrane of graft target cells and polymerize to form pores that 
subsequently allow ion fluxes and entrance of cytolytic proteases, thus leading to 
cell death (Reviewed in Berke, 1991). 
Furthermore, although the importance of specific anti-graft antibodies in 
acute rejection is uncertain, B lymphocytes are also known to be activated by T 
cell products in the presence of antigen to produce high levels of anti-class I 
antibodies. These antibodies are thought to be important in hyper acute 
rejection, accelerated vascular rejection, and antibody-dependent-cell-mediated 
cytotoxicity (Morris et al., 1990). 
Production of Inflammatory Mediators 
Promotion of allograft rejection by infiltrating cells may also occur 
indirectly, through effects resulting from the local release of inflammatory 
mediators which cause subsequent graft cell death. Production of these 
mediators may either directly injure graft target cells themselves, or do so by 
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recruiting and activating nonspecific components of graft destruction. Halloran 
et al (1989) summarized the relevance some of these inflammatory mediators 
have to the rejection process. These include: 1) the activation of macrophages as 
well as inhibition of their migration from the graft (primarily by IFNy), leading to 
increased macrophage release of cytokines (IL-1 and TNFa), eicosanoids, and 
reactive oxygen intermediates; 2) the recruitment (by IL-l,IL-8, and other 
chemokines) of polymorphonuclear leukocytes; 3) secondary effects of platelet 
and coagulation activation which leads to graft ischemia; and, 4) the direct, 
nonspecific cell necrosis capability of TNF, and perhaps IL-1 and IFNy, at 
concentrations found within acutely rejecting grafts (Reviewed in Halloran et al., 
1989). 
Taken together, both specific and nonspecific components of allograft 
rejection leads, in the absence of immunosuppression, to an intense immune cell 
infiltrate and subsequent graft cell destruction observed in acute rejection. 
The focus of this dissertation is the investigation of the role of certain 
soluble mediators of the immune response produced during rat cardiac allograft 
rejection is investigated. A subset of these proteins which are known to be toxic 
to cells, including the cytokines TNFa and LT, and the granzymes A and B (HF 
and Cll, respectively), were evaluated for their role(s) in the host's response to 
transplanted rat cardiac tissue. Insight into which of these cytotoxic proteins are 
produced, and when during the course of allograft rejection, may provide 
opportunities for both the detection of early markers of graft rejection and the 
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design of improved immunosuppressive therapies which may be used to 
prolong graft survival. 
Cytokines and Granzymes in Allograft Rejection 
Historical Background 
As previously stated, the immune process in response to alloantigen is in 
part due to the production by different cell types of soluble endogenous 
biological mediators, among which are cytokines. Cytokines are soluble proteins 
produced by a variety of hematopoietic cells that have the ability to regulate the 
local development of alloreactivity. Cytokines can promote graft rejection by 
increasing MHC class II antigen expression (Hall et al., 1984; Fuggle et al., 1987), 
inducing adhesion molecule expression (Reviewed in Pober & Cotran, 1990), 
providing growth and differentiation signals to effector cells, and in some cases, 
directly damaging the graft parenchyma (Halloran et al., 1989). 
Initial studies investigating the relevance of cytokines to allograft 
rejection have taken advantage of the development of specific immunoassays 
and bioassays that allow measurement of the cytokines of interest in biological 
fluids. Generally, the strategy has been to measure specific cytokines in the 
blood or urine of transplant recipients prior to, and following, graft 
transplantation, and to attempt to correlate changes in cytokine levels with 
clinical status. Identification of a given cytokine during rejection episodes 
suggests but does not prove its participation in the rejection process. 
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Several investigators have reported increased serum or plasma levels of 
TNFa (Maury & Teppo, 1987; Hoffman et al., 1991), IL-1~ (Tilget al., 1990; 
Hoffman et al., 1991), and IL-6 (Caillat-Zuckman et al., 1991) in patients at the 
time of acute rejection episodes. Additionally, elevated levels of TNFa have also 
been detected in the urine of rejecting human transplant recipients (McLaughlin 
et al., 1991). In patients receiving renal allografts, increased IL-2 (McKenna et al., 
1988) and IL-2 receptor (Simpson et al., 1989) levels were observed in the 
periphery during acute rejection episodes. However, IL-2 and IL-2 receptor, 
along with TNFa, were also found to be significantly increased during bacterial 
or viral infection (Maury & Teppo, 1987; McKenna et al., 1988; Simpson et al., 
1989; Imagawa et al., 1990a). Therefore, although changes in peripherally-
measured cytokines often accompany allograft rejection and may provide 
information concerning the events occurring within the graft, the specificity of 
the data recovered, especially regarding their role in the pathogenesis of the 
acute rejection process, is very difficult to interpret. 
In fact, systemic or circulating cytokine levels may not accurately reflect 
events occurring in the local intragraft environment. Although elevated 
circulating proinflammatory cytokines are found during acute rejection, 
infections in general and viral infections in particular, may elicit the same pattern 
of cytokine expression. In addition, it has previously been shown that cytokines 
may circulate bound to other proteins, such as natural inhibitors (Larrick, 1989), 
soluble receptors (Dinarello et al., 1993), preformed auto antibodies (Bendtzen et 
al., 1990), and a2-macroglobulin Games, 1990), which inhibit their biological 
activity but do not affect their immunoreactivity. Detection of an abnormally 
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elevated cytokine in the systemic circulation does not necessarily prove that the 
mediator is biologically active. Therefore, in situ measurement of these immune 
mediators at the graft site is a far more accurate and reliable method of 
identifying the cytokines elaborated during allograft rejection. 
Cytokine Production Within Rejecting Allografts 
During the last few years, the development of sensitive molecular 
techniques that allow identification of cytokine mRNA in small amounts of tissue 
or in limited numbers of cells has been paramount in characterizing the local 
cytokine pathways that are elaborated during allograft rejection. For example, in 
situ hybridization, as well as polymerase chain reaction (PCR) amplification have 
recently been employed to address this issue. Recently, IL-6, TNFa, and IFNy 
gene expression was examined by in situ hybridization techniques in human 
renal allografts (Vandenbroeke et al., 1991; Noronha et al., 1992). It was found 
that the majority of samples taken from rejecting kidneys contained elevated 
levels of IL-6 gene transcripts, which were localized within glomerular cells, 
endothelium, tubular epithelia, and the infiltrate; IFNy and TNFa mRNA, 
however, were not found to be associated with rejection. These findings 
implicate a role for IL-6 in the pathogenesis of human kidney allograft rejection. 
Krams, et al. analyzed cytokine gene expression by PCR amplification in 
both rejecting and rejected renal allografts (Krams et al., 1992). IL-1~, IL-6, and 
TNFa gene transcripts were prominent in rejected allografts, (supporting the 
concept that end-stage transplants are sites of ongoing inflammation); IL-6 and 
TNFa mRNA transcripts were detected less frequently in rejecting allografts than 
rejected allografts, while IL-1~ mRNA was not evident. Conversely, gene 
15 
transcripts for the immune mediators IL-2, IL-4, and IL-5 were more prevalent in 
rejecting allografts than in end-stage transplants, suggesting that different 
immunologic processes may predominate depending on the progression of 
rejection. Wu et al (1992), also utilized the methodology of PCR amplification to 
detect cytokine mRNA transcripts in biopsies obtained from heterotopic 
abdominal cardiac allografts. IFNy mRNA transcripts were detected in all 
transplants two days after surgery, before evidence of rejection was 
demonstrable by histopathologic analysis. IL-1~, IL-2, and IL-6 gene transcripts 
were detected when minimal rejection was noted, and IL-la, IL-1~, IL-2, IL-6, IL-
8, TNF~ (LT), and IFNymRNA transcripts were detectable in end-stage 
transplants (Wu et al., 1992). 
Recently, Lipman, et al (1992) investigated cytokine gene expression for IL-
1~, IL-2, IL-6, TNFa, and the cytotoxic T cell-specific serine protease, Cl1, in 
biopsies obtained from human renal allografts. The core biopsies were classified 
into three different categories based on histology: no evidence of rejection, acute 
cellular rejection, and equivocal rejection. IL-1~, IL-2, IL-6, and TNFa mRNA 
transcripts were detected in all biopsy classifications, with no difference in the 
frequency of gene expression of any of the aforementioned cytokines in relation 
to histology. However, C11 gene expression notably correlated with rejection. 
These results support a primary role for cytotoxic T lymphocytes in the cellular 
mechanisms of renal allograft rejection. 
Although specific mechanisms have not yet been elucidated, there is 
enough data to indicate that cytokines play an important role in the pathogenesis 
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of allograft rejection, and may prove to be a useful target to disrupt the rejection 
process. In the present dissertation, employment of the previously mentioned 
methodology, that is, intragraft measurement of specific cytokines in 
transplanted rat cardiac tissues, is utilized to detect cytotoxic cytokine levels 
during the evolution of graft rejection. Specifically, TNFa and LT, as well as two 
cytotoxic T cell-specific serine proteases of the granzyme family, HF and Cll, 
will be examined for their putative roles in the rejection process of 
heterotopically transplanted rat cardiac allografts. 
Tumor Necrosis Factors-a and -6 
TNFa and -~ (LT) are two closely related cytokines that are endogenous 
mediators of immunological and inflammatory events. TNFa is a small peptide 
cytokine with a molecular weight of 17 kD which is produced primarily by 
activated macrophages (Beutler et al., 1985a), but recently has also been shown to 
be synthesized by activated peripheral T lymphocytes (Steffen et al., 1988). LT is 
a glycoprotein with a molecular mass of 25 kD originally identified as a cytolytic 
factor produced by cultured T lymphocytes in response to challenge with an 
antigen to which the cells had previously been exposed in vivo (Ruddle & 
Waksman, 1967), or in response to nonspecific mitogenic stimuli, (i.e., lectins) 
(Granger & Williams, 1968). TNFa and LT share 36% and 51 % structural 
homology in overall nucleotide and amino acid sequences, respectively (Pennica 
et al., 1984), and also appear to have common receptor-binding domains 
(Aggarwal et al., 1985a). 
Although TNFa and LT are distinct biochemically, they exert similar 
immunological effects in vitro (Ruddle, 1985; Beutler & Cerami, 1986). One of 
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the many biological activities of TNFa and LT includes activation of 
macrophages and enhancement of their cytotoxic potential in vitro (Aggarwal et 
al., 1985b). In addition to their cytotoxic effects, TNFa and LT have been shown 
to activate T lymphocytes, B lymphocytes, and NK cells (Yokota et al., 1988; 
Kehrl et al., 1987), and to elicit an increase in IL-1 and IL-6 synthesis and IL-2 
receptor expression by cultured macrophages and T cells (Beutler et al., 1985b). 
The specific roles of TNFa and LT in allograft rejection, however, are less 
well defined. As previously mentioned, TNFa has many proinflammatory 
actions which have been implicated to contribute to the allograft rejection 
response. These effects include: potent induction of chemotactic factors for 
polymorphonuclear leukocytes and monocytes (Baggiolini et al., 1989), which 
may cause infiltration of these effector cells to the graft site, augmentation of 
class I MHC antigen expression (Tracey et al., 1987)), stimulation of endothelium-
derived platelet activating factor, promoting ischemia within the graft, and 
induction of macrophage activation. 
Macrophages, in fact, have been shown to be major components of the 
cellular infiltrate in transplanted organs undergoing rejection (Strom et al., 1977), 
and have been implicated as an effector cell in first-set (acute) allograft rejection 
(MacPherson & Christmas, 1984). Macrophage numbers have been shown to 
dramatically increase during rejection (Leendert et al., 1992), and have been 
described to be the predominant infiltrating cell at the time of rejection 
(Christmas & MacPherson, 1982; Forbes & Guttmann, 1983). Furthermore, 
macrophages can act as antigen presenting cells that have the ability to induce 
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immune responses, and as effector cells able to cytotoxically damage and cause 
eventual necrosis of graft target cells (Nathan et al., 1980). For these reasons, the 
present dissertation investigates TNFa, primarily an activated macrophage cell 
marker, for its possible role during the process of acute allograft rejection of rat 
cardiac transplants. Additionally, because TNFa and LT are known to exert 
similar immunological effects (Ruddle, 1985; Beutler & Cerami, 1986), and in 
fact, bind to common receptor domains (Aggarwal et al., 1985a), the studies 
contained within this dissertation also examined the putative role LT may 
contribute to acute rejection of rat cardiac allografts. 
It has previously been reported that a marked elevation of serum TNFa 
levels exists during rejection episodes in human renal allograft recipients (Maury 
& Teppo, 1987). In addition, serum TNFa levels in cardiac allograft recipients 
have been shown to correlate with severity of rejection based on histological 
assessment of endomyocardial biopsies Gordan et al., 1993). TNFa activity has 
also been demonstrated in homogenates from rejecting rat cardiac allografts 
(Lowry & Blais, 1988), and localized to mononuclear cell infiltrates in increased 
amounts during rejection (Hancock et al., 1991). Cytotoxic activity, attributed to 
LT, has been reported in both rejecting human (Moy & Rosenau, 1981) and rat 
(Lowry et al., 1985b) renal allografts. Recent studies have reported successful use 
of anti-TNFa and LT antibodies in prolonging the survival of transplanted grafts 
(Imagawa et al., 1990b; Scheringa et al., 1991; Teramoto et al., 1991), as well as 
reducing cellular infiltrates and edema (Saito et al., 1993) in rat models of 
rejection, indicating the contribution of TNF in mediating acute rejection. These 
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data strongly suggest a role for TNFa and/ or LT in the pathogenesis of allograft 
rejection. 
Granzymes A and B (HF and Cll) 
Granzymes are a family of highly homologous serine proteases present in 
secretory granules of cytolytic T lymphocyte cells. Seven serine proteases have 
been identified (granzymes A through G) (Reviewed in Masson & Tschopp; 
Jenne & Tschopp, 1988) from cytolytic granules of murine cytotoxic T 
lymphocytes and NK cells, and four serine proteases have been identified from 
human cytolytic lymphocytes (granzymes A, B, 3, and H) (Reviewed in Griffiths 
& Mueller, 1991a). Besides granzymes, perforin and proteoglycan molecules of 
the chondroitin sulfate A type, are the other two major constituents of these 
cytolytic granules (Krahenbuhl & Tschopp, 1991). Granzymes have been 
implicated in cell-mediated lysis by the observation that lysis by cloned T cells 
and isolated granules is inhibited by treatment with serine protease inhibitors 
(Chang & Eisen, 1980; Acha-Orbea et al., 1983). However, the physiologic role of 
granzymes is unknown. There is considerable evidence that the cytolytic 
granular components of cytotoxic T cells are released upon effector-target cell 
binding (Bykovaskaja et al., 1978). In fact, granzymes and proteoglycan 
molecules have been detected in the culture medium of cytotoxic T lymphocyte-
target cell conjugates (Pasternack et al., 1986; Takayama et al., 1987). Granzymes 
by themselves, however, do not have cytolytic activity (Masson & Tschopp, 1985; 
Podack et al., 1985). Yet in combination with purified perforin, granzymes can 
affect the release of target cell DNA, an event which occurs during cell-mediated 
lysis (Hayes et al., 1989). 
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An attractive model for "lethal hit delivery" has been proposed describing 
the events leading to target cell lysis. This granule-exocytosis model suggests 
that, upon appropriate effector-target cell conjugation, the effector cells deliver 
dense cytoplasmic granules and their contents into the intercellular space at the 
site of contact between the target and effector cell (Sitkovsky, 1988). This process 
of degranulation releases perforin, which, upon polymerization and in the 
presence of Ca2+, induces transmembrane, ring-like pores in the target cell 
membrane. The formation of pores in the target cell membrane subsequently 
allows ion fluxes and access to the released granular contents, including 
granzymes, which leads to target cell apoptosis and eventual cell death (Berke, 








Fig. 3. Proposed granule-exocytosis model for "lethal hit delivery," leading to 
target cell lysis. 
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As stated earlier, cytotoxic T lymphocytes are believed to be important 
effector cells in the destruction of transplanted tissue during allograft rejection 
(Loveland & McKenzie, 1982; Lowry et al., 1985b). After recognition of 
alloantigens on the surface of MHC-nonidentical target cells, cytotoxic effector 
cells bind to them and induce target cell lysis (Hall et al., 1978). Although various 
steps in this process have been analyzed in considerable detail, most studies have 
not provided insight into the mechanism(s) by which the cytolytic effector cell 
administers the "lethal hit" to the target cell. Recently, the genes encoding the 
serine esterases HF and Cll (Granzymes A and B, respectively), which have been 
demonstrated to be selectively expressed in cytotoxic cells including cytotoxic T 
lymphocytes and NK cells, have been cloned (Gershenfield & Weissman, 1986; 
Lobe et al., 1986). The kinetics of HF and Cll gene expression closely parallel the 
cytolytic responses in vitro, in that the observed kinetics of serine esterase release 
and of the delivery of the lethal hit are consistent with the hypothesis that both 
events occur simultaneously (Gershenfield & Weissman, 1986; Lobe et al., 1986). 
Therefore, a strong correlation exists between granzyme gene expression and 
cytotoxic potential. For these reasons, this dissertation investigated the 
expression of both HF and Cl 1 serine proteases for their putative role in the 
process of acute allograft rejection of rat cardiac transplants. 
One of the first studies demonstrating the importance of granzyme-
expressing lymphocytes in vivo, involves the detection of transcripts encoding 
serine proteases in situ, during murine cardiac allograft rejection (Mueller et al., 
1988). In this study, the time course of serine protease expression closely 
paralleled the rejection process. Recently, both granzymes A and B have been 
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described as putative markers for rejection in patients following cardiac 
transplantation (Griffiths et al., 1991b; Clement et al., 1991), as well as in 
experimental animal models of cardiac (Mueller et al., 1991) and renal (Lipman et 
al., 1992) allograft rejection. Therefore, these data would suggest that cytotoxic 
cell-specific serine proteases, such as HF and Cl 1, may play a role in the 
pathogenesis of rat cardiac allograft rejection. 
Immunosuppression to Prevent Allograft Rejection 
Historical Background 
Therapeutic attempts to prevent allograft rejection have gradually evolved 
from nonspecific suppression of immune responsiveness to the modulation of 
specific components of rejection. In the late 1950s, a single incidence of long-term 
success was achieved with total body irradiation for a human renal allograft 
transplanted into a fraternal twin recipient (Murray et al., 1960). In the early 60s, 
Caine, et al (1962) demonstrated the usefulness of mercaptopurine, a purine 
analog antimetabolite that nonspecifically inhibits gene replication therefore 
affecting T cell proliferation and antibody synthesis. In this study, 
mercaptopurine was found to be successful in prolonging canine renal allografts, 
and soon after, its parent compound, azathioprine, became commonly used in 
clinical settings. Subsequently, the beneficial synergistic effect of steroids with 
azathioprine was realized, and the introduction in the 1960s of antilymphocyte 
serum in conjunction to this combination therapy, especially for the reversal of 
acute rejection, came into use (Reviewed in Murray et al., 1981). However, 
adverse side effects, including leukopenia, thrombocytopenia, and allergic 
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reactions to heterologous serum as well as anti-lymphocyte serum antibody 
production limited its long-term use. 
The decade of the 1980s was highlighted by the introduction and 
application of cyclosporine A (CSA) in the field of organ transplantation. CSA 
was first used clinically in 1978 (Caine et al., 1978), and because it was 
demonstrated to be a potent immunosuppressive agent acting at the level of the 
T lymphocyte, CSA was subsequently used therapeutically following organ 
transplantation. 
Cyclosporine A 
CSA is a cyclic endecapeptide derived from the soil fungus, Tolypocladium 
infiatum, and as stated earlier, has been demonstrated to be a potent 
immunosuppressive agent and inhibitor of helper T cell function (Borel et al., 
1976; Orosz et al., 1983). The profound, reversible suppression of cell-mediated 
immunity caused by CSA was first described by Borel et al (1976), and since those 
landmark studies, it has been the focus of numerous investigations to examine its 
exact mechanism(s) of action. CSA has been shown to consistently inhibit IL-2 
gene transcription (Kronke et al., 1984; Elliot et al., 1984), and therefore, the direct 
effects of CSA upon CD4 + T helper lymphocytes have become the central focus of 
most efforts attempting to elucidate CSA's immunosuppressive action, since one 
functional characteristic of the CD4+ T helper lymphocyte population is the 
biosynthesis and release of an array of cytokines, including IL-2. 
IL-2 is a T helper cell product that functions as a second signal in the 
presence of appropriate antigen to promote the differentiation and clonal 
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expansion of mature T lymphocytes and appears to be an important mediator in 
allograft rejection, since a positive correlation between IL-2 levels and rejection 
episodes has been described (Yoshimura & Kahan, 1985; Vie et al., 1985; 
McKenna et al., 1988). Anti-IL-2 receptor antibodies have also been shown to 
prevent allograft rejection in experimental models, thus supporting the central 
role IL-2 plays in the rejection process (Kirkman et al., 1985). Although CSA's 
action on IL-2 gene expression in T cells is currently taken as the prototype for all 
its immunosuppressive effects, CSA also has effects on many other cell types, 
and on their cytokine production. In mast cells, CSA has been demonstrated to 
block degranulation as well as transcriptional activation of several cytokine 
genes, including IL-3 and IL-5 (Cirillo et al., 1990; Hultsch et al., 1991). In 
stimulated THP-1 cells, a leukemic monocyte cell line, CSA has been shown to 
inhibit the in vitro production of both IL-la and IL-1~ (Reisman et al., 1991). CSA 
has also been reported to inhibit in vitro-stimulated cytokine production by 
peripheral blood mononuclear cells; these cytokines include IL-2, IFNy, IL-4, IL-5, 
and TNFa (Andersson et al., 1992). 
As stated earlier, most studies investigating the actions of CSA have 
concentrated on T cells as the targets for CSA immunosuppression. However, 
recent attention has also focused on the role of the macrophage. Benson et al 
(1989) demonstrated that decreased IL-2 production observed with CSA 
treatment is actually caused by inhibition of macrophage antigen presentation. 
Additionally, in vitro studies have shown that CSA inhibits production of TNF 
(Espevik et al., 1987) without depressing mRNA or intracellular levels of TNF 
(Remick et al., 1989). CSA has also been shown to block the extracellular 
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production of TNF in response to lipopolysaccharide (LPS) challenge, both in 
vitro and in vivo, without decreasing TNF mRNA (Nguygen et al., 1990). 
Therefore, although CSA is generally accepted to act as an immunosuppressive 
agent through potent inhibition of IL-2 production by T cells, CSA may also exert 
its immunosuppressive actions through inhibition of additional cytokines 
produced by different leukocyte populations. 
While CSA effects upon cytokine biosynthesis and release have been 
reproducibly demonstrated, the exact mechanism of CSA action remains to be 
characterized. CSA is thought to enter target cells through passive transport by 
diffusing through the plasma membrane lipid bilayer (LeGrue & Munn, 1986a), 
concentrating on the inner membrane surface, and presumably gaining 
intracellular access from that point (Rossaro et al., 1988). Investigation has 
revealed that CSA binds to a number of intracellular proteins in extremely small 
quantities with two notable exceptions. Calmodulin, a calcium binding protein 
which undergoes a conformational change upon receptor-ligand interaction, 
binds to CSA; however, the interaction is of relatively low affinity and has not 
been linked to the biologic effects mediated by CSA (Hess et al., 1988; LeGrue et 
al., 1986b). At high concentrations, CSA does exert some effects upon 
calmodulin, but the collective data have argued against the interaction 
representing a primary component of CSA's mechanism of action (Drugge & 
Handschumacher, 1988). 
Recently, the binding of CSA to an intracellular protein, cyclophilin, has 
been reported (Handschumacher et al., 1984). Subsequent protein purification 
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and sequence determination has revealed cyclophilin to represent a novel 
molecule 17 kD in size and characterized by its ability to bend or fold proteins at 
praline groups, from the "cis" to the "trans" position, and therefore described as a 
peptidyl-prolyl cis-trans isomerase (Harding et al., 1986; Takahashi et al., 1989; 
Fischer et al., 1989). CSA is thought to inhibit the rotomase enzyme activity of 
cyclophilin. It has been postulated that CSA's immunosuppressive effect is due 
to the inhibition of cyclophilin's isomerase activity, needed for signal 
transduction (Lorber et al., 1990). 
More recent evidence has shown that CSA specifically inhibits the DNA 
binding activities of several nuclear factors important in transcriptional 
activation of the genes for IL-2 and several other cytokines (Emmel et al., 1989; 
Mattila et al., 1990). Specifically, the transcription factors NF-AT, AP-3, NF-AL, 
and NF-KB, were found to be affected by CSA; each of these transcription factors 
have a common distinguishing feature in that all require Ca2+ mobilization for 
activation. Therefore, the aforementioned observations have led to a working 
hypothesis proposed by Schreiber et al (1992) by which CSA blocks IL-2 gene 
activation, and possibly other cytokines, in T cells and other immune cell 
populations (summarized in Figure 4). 
In addition to its immunosuppressive capabilities, CSA has also been 
shown to mediate a number of physiologic changes; the clinical manifestations of 
these effects often resulting in toxic side effects. Therefore, although CSA has 
been used with considerable success clinically to prolong organ graft survival, 
significant adverse side effects, such as nephrotoxicity (Myers et al./, 1984), 
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Fig. 4. Proposed model of CSA inhibition of cytokine (IL-2) gene activation. 
Binding of antigen to TCR leads to intracellular Ca2+ release. Calcium activates 
the phosphatase, calcineurin which, in the absence of CSA, dephosphorylates 
NF-ATc (cytosolic subunit) thus facilitating its translocation into the nucleus. 
NF-ATc can then combine with NF-ATn (nuclear cofactor) to form an activated 
transcription factor with the ability to activate RNA polymerase, thereby 
regulating gene transcription. This process is blocked when CSA binds to its 
receptor protein, cyclophilin. The CSA-cyclophilin complex can inhibit 
calcineurin, which blocks nuclear translocation of NF-ATc, therefore inhibiting 
cytokine gene activation. 
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hepatotoxicity (Vine et al., 1988), hypertension (Munoz et al., 1988), as well as 
neurological toxicities (deGroen et al., 1987) have been reported with its use. 
Consequently, a need remains for implementing specific therapies directed at 
achieving transplant success with a minimum of undesirable side effects. 
As newer agents with immunosuppressive capabilities appear on the 
horizon, the possibility of utilizing combination treatments has offered hope for 
improved therapeutic management of organ transplantation. For example, the 
introduction of both FK506 (Tanaka et al., 1987), an antibiotic tacrolimus isolated 
from the soil fungus Streptomyces tsukubaenis, and rapamycin (Seghal et al., 1975), 
another macrolide similar in structure to tacrolimus, have demonstrated potent 
immunosuppressive activity (Beck & Akiyama, 1989; Morris et al., 1990). 
Rapamycin, in particular, has been shown to exhibit marked synergy when 
combined with CSA in inhibiting various parameters of in vitro immunological 
performance by human peripheral blood lymphocytes (Kahan et al., 1991). 
Monoclonal antibodies, such as OKT3, a murine monoclonal antibody against the 
CD3 complex, have also shown promising results in the clinical management of 
organ transplantation (Millis et al., 1989). Although these immunosuppressive 
agents have demonstrated initial clinical success, their mechanisms of action as 
well as their use in organ transplantation therapy will not be discussed in detail 
within the present dissertation, but are reviewed elsewhere (Metcalf & Richards, 
1990; Schreiber & Crabtree, 1992). It may be said, however, that despite their 
promising immunosuppressive effects, FK506, rapamycin, and OKT3, similar to 
CSA, all have certain adverse side effects associated with their use at therapeutic 
doses. One possible approach to forego high dose toxicities is the utilization of 
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combination treatments, administered at lower therapeutic doses, to achieve 
increased survival time of organ transplants while minimizing adverse side 
effects. 
Methotrexate 
One agent which may provide promising results for combination therapy 
is methotrexate (MTX). MTX is classified pharmacologically as an antimetabolite 
because of its antagonistic effect on folic acid metabolism and function (Mitchell 
et al., 1969). MTX has been shown to bind dihydrofolate reductase which results 
in the inhibition of DNA synthesis; this antiproliferative action has made MTX a 
useful drug for cancer chemotherapy 0olivet et al., 1983). Compared to CSA, 
little is known about the immunosuppressive actions of MTX. However, the 
importance of MTX as an immunosuppressive agent was first considered when 
anti-inflammatory effects were noticed with its utilization in the treatment of 
rheumatoid arthritis, wherein MTX demonstrated both long term and short term 
efficacy (Weinblatt et al., 1985; Perhala & Wilke, 1991). The mechanism(s), 
however, by which MTX suppresses disease activity in inflammatory rheumatoid 
arthritis is still poorly understood and adverse side effects, such as severe 
leukopenia and gastrointestinal upset, have been associated with its use 
(Weinblatt et al., 1985). 
It has been postulated that MTX may exert its immunosuppressive action 
by deactivation of macrophages. This would result in decreased IL-1 production 
(Hu et al., 1988), as well as inhibition of macrophage migration, resulting in the 
decreased accumulation of inflammatory cells and/ or immune mediators 
0ohnson et al., 1988). Despite these findings, the administration of MTX has also 
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been shown to restore both T cell function (Kourounakis & Kapusta, 1976) and 
IL-2 production (Combe et al., 1985) in rheumatoid arthritis, thereby 
counteracting the immunosuppressive effects demonstrated by Hu et al (1988). 
MIX, however, has recently shown favorable results in treating 
persistent mild (Olsen et al., 1990), as well as recurrent moderate to severe cardiac 
allograft rejection (Costanzo-Nordin et al., 1988). Success has also been 
demonstrated using CSA at doses of 10-15 mg/kg/ day combined with either 
high or low dose MIX in the prevention of graft-versus-host disease after bone 
marrow transplantation in experimental animal models (Deeg et al., 1982; Deeg 
et al., 1984), as well as in human clinical studies (Storb et al., 1986; Truog & 
Wozniak, 1990). 
Taken together, immune processes in response to alloantigen is the 
result of both direct cell-mediated events and the production of, by different cell 
types, soluble biological mediators, including cytokines and granzymes. In the 
absence of immunosuppression, these specific and non-specific components of 
allograft rejection lead to intense immune cell infiltration and subsequent graft 
cell destruction. Previous observations strongly suggest that administration of 
CSA/MIX combination therapy may serve as a possible alternative treatment in 
promoting allograft survival. Figure 5 summarizes the postulated mechanisms 
of CSA/MIX immunosuppression on effector cells and cytokine/granzyme 
production during allograft rejection. For these reasons, the focus of the present 
dissertation is to examine the effects of a low dose CSA/MIX combination 
therapy in prolonging rat cardiac allografts. Specifically, low dose CSA/MIX 
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combination therapy will be evaluated for its ability to prolong rat cardiac 
allograft survival time, as well as for its effect on cytotoxic cytokine expression, 
including TNFa, LT, and granzymes A and B (HF and Cl1). 
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Fig. 5. Possible mechanisms of CSA/MTX immunosuppression on effector cells 
and cytokine/ granzyme production during allograft rejection. 
Therefore, the major objectives of this dissertation project are: 1) to 
quantitate the expression of the aforementioned cytotoxic cytokine gene products 
during the evolution of graft rejection, and 2) to evaluate and compare the 
efficacy of a low dose CSA/MTX combination therapy for its ability to prolong 
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survival of rat cardiac allografts. These objectives will be fulfilled by 
accomplishing the following specific aims: the expression of the genes encoding 
the cytotoxic cytokines, TNFa and LT (Chapter II) and the serine proteases HF 
and C11 (granzymes A and B, respectively) (Chapter IV), are quantitated during 
rat cardiac allograft rejection. In Chapter III, the aims are: 1) to evaluate the 
efficacy of a low dose CSA (1.0 mg/kg/day)/MTX (450 µg/kg/wk) combination 
therapy in prolonging rat cardiac allograft survival, and 2) to determine the 
effects of low dose CSA/MTX on IL-2 gene expression in rat cardiac allografts. 
Finally, in Chapter IV, the effects of low dose CSA/MTX on the expression of the 
cytotoxic cytokines, TNFa, LT, as well as the serine proteases HF and C11, are 
determined in rat cardiac allografts during rejection. 
Insight into which of the cytotoxic mediators are synthesized, and when 
post-tx, may provide opportunities for early detection of molecular "markers" 
that signal impending rejection. Assessment of the cytokine profile during 
allograft rejection may also aid in the development of more specifically targeted 
immunosuppressive therapies designed to prolong graft survival. Therefore, the 
overall goal of these studies is to expand our knowledge of the 
immunopathological mechanisms involved in graft rejection and to evaluate 
more effective strategies aimed at prolonging graft survival while minimizing 
adverse side effects often associated with the use of immunosuppressive agents. 
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CHAPTER2 
INDUCTION OF TNFa AND TNF~ GENE EXPRESSION IN RAT CARDIAC 
TRANSPLANTS DURING ALLOGRAFT REJECTION 
Abstract 
The expression of the cytotoxic cytokines, TNFa and LT, was assessed in 
rat cardiac transplants during rejection. Newborn rat cardiac grafts placed in 
adult rat ear pinnae were retrieved on days 1 through 10 post-transplantation 
(post-tx); the average time to rejection, assessed by the absence of detectable 
electrocardiographic (ECG) activity, was determined to be 7 days. Total cellular 
RNA and tissue homogenates were prepared from cardiac transplants in order 
that relative levels of TNFa and LT mRNA and TNF protein could be 
determined. A biphasic pattern of TNFa gene expression was consistently seen 
in cardiac allografts. TNFa mRNA transcripts were detected as early as day 2 
post-tx, with peak levels appearing on day 3 post-tx. Although transcript levels 
decreased by day 4, a significant increase appeared again on day 6 post-tx, 
coincident with the onset of rejection. Similar to TNFa gene expression, LT 
transcripts demonstrated a biphasic pattern of induction. LT mRNA transcripts 
also reached peak levels on day 3 post-tx, with a second increase in transcript 
levels coincident with rejection. TNF protein levels in allografts displayed a 
biphasic pattern, similar to that shown by the cytokine mRNAs. Peak levels of 
TNF protein were detected on day 3 post-tx, with a second increase again 
coinciding with rejection. In contrast to TNF expression found in allografts, 
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TNFa and LT mRNA transcripts were not detected in isografts on days 1 through 
10 post-tx. TNF protein levels in cardiac isografts were consistently at or below 
the standard limits of detection, and on days 3 through 7 post-tx were 
significantly reduced (p ~ 0.001) when compared to time-matched allografts. 
Increased expression of the cytotoxic cytokines, TNFa and LT, therefore, appears 
to be allograft-specific and is an early event during rat cardiac allograft rejection. 
In conclusion, induction of TNF gene expression may be an important early 
indicator of transplant rejection. 
Introduction 
Although the immunological basis for transplant rejection has been well 
established, the cellular mechanisms responsible for allograft rejection have not 
yet been fully elucidated. After transplantation of a tissue allograft, a cellular 
infiltrate consisting of leukocytes of several phenotypes appears within the graft 
(Hanto et al., 1982). Infiltration of both helper and cytotoxic T lymphocytes 
precedes the destruction of the allograft by several days, and it is believed that 
these cells play a major role in the process of allograft rejection (Loveland & 
McKenzie, 1982; Lowry et al., 1983). Macrophages and NK cells have also been 
found to be major components of the cellular infiltrate in organ allografts 
undergoing acute rejection (Strom et al., 1977; MacPherson & Christmas, 1984; 
Nemlander et al., 1983). These cells proliferate and release a range of soluble 
mediators of the immune response (i.e., cytokines) - which, among many other 
effects, have been shown to damage blood vessels within the graft (Dvorak et al., 
1980), cause an increase in graft infiltration by leukocytes (Cox et al., 1984), and 
stimulate the differentiation of graft-specific T cells at the graft site (Heidecke et 
al., 1984). These events precipitate allograft damage and eventual necrosis of the 
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transplanted tissue. There are two principal mechanisms by which cell-mediated 
injury may occur: through direct lysis of the graft target cells, or indirectly, 
through local production of cytokines which, in turn, contribute to allograft 
destruction. 
TNFa and LT are two closely related cytokines that are endogenous 
mediators of immunological and inflammatory events. TNFa is a small peptide 
cytokine with a molecular weight of 17 kD which is produced primarily by 
activated macrophages (Beutler et al., 1985a), but recently has also been shown to 
be synthesized by activated peripheral T lymphocytes (Steffen et al., 1988). LT is 
a glycoprotein with a molecular mass of 25 kD originally identified as a cytolytic 
factor produced by cultured T lymphocytes in response to challenge with an 
antigen to which the cells had previously been exposed in vivo , or in response to 
nonspecific mitogenic stimuli, (i.e., lectins) (Ruddle & Waksman, 1967; Granger 
& Williams, 1968). TNFa and LT share 36% and 51 % structural homology in 
overall nucleotide and amino acid sequences, respectively (Pennica et al., 1984), 
and also appear to have common receptor-binding domains (Aggarwal et al., 
1985a). 
Although TNFa and LT are distinct biochemically, they exert similar 
immunological effects in vitro (Beutler & Cerami, 1986; Beutler, 1990). One of 
the many biological activities of TNFa and LT includes activation of 
macrophages and enhancement of their cytotoxic potential in vitro (Aggarwal et 
al., 1985b). In addition to their cytotoxic effects, TNFa and LT have been shown 
to activate T lymphocytes, B lymphocytes, and NK cells (Yokota et al., 1988; 
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Kehrl et al., 1987), and to elicit an increase in IL-1 and IL-6 synthesis and IL-2 
receptor expression by cultured macrophages and T cells (Beutler et al., 1985b). 
The specific roles of TNFa and LT in allograft rejection, however, are less 
well defined. It has been reported that a marked elevation of serum TNFa levels 
exists during rejection episodes in human renal allograft recipients (Maury 
&Teppo, 1987). Similarly, serum TNFa levels have been found to be significantly 
elevated in patients experiencing acute rejection following orthotopic liver 
transplantation (lmagawa et al., 1990a). TNFa activity has also been 
demonstrated in homogenates from rejecting rat cardiac allografts (Lowry & 
Blais, 1988) and localized to mononuclear cell infiltrates in increased amounts 
during rejection (Hancock et al., 1991). Cytotoxic activity, attributed to LT, has 
been reported in both rejecting human (Moy & Rosenau, 1981) and rat (Lowry et 
al., 1985b) renal allografts. Recent studies have reported successful use of anti-
TNFa and LT antibodies in prolonging the survival of transplanted grafts in 
experimental animals, indicating the contribution of TNF in mediating acute 
rejection (Imagawa et al., 1990b; Scheringa et al., 1991; Teramoto et al., 1991). 
These data strongly suggest a role for TNFa and/or LT in the pathogenesis of 
allograft rejection. 
The purpose of this study was to quantitate the expression of the genes 
encoding these two cytokines during rat cardiac allograft rejection. Insight into 
which of these two cytotoxic proteins are synthesized, and when post-tx, may 
provide opportunities for early detection of cytokine "markers" that signal 
impending rejection. Assessment of the cytokine profile during allograft 
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rejection may also aid in the development of more specifically targeted 
immunosuppressive therapies designed to prolong graft survival. 
Materials and Methods 
Animals 
Pregnant Brown Norway (BN) (RTln) and 6-8-week-old male Lewis 
(RTll) rats were purchased from Harlan Sprague Dawley (Indianapolis, IN). 
Dark Agouti (DA) (RTla) rats were obtained from an inbred rat colony 
maintained at Loyola University Medical Center. All animals received water and 
food ad libitum, and were housed in accordance with institutional animal care 
and use guidelines. Two isograft groups were used in these studies: adult male 
Lewis or DA rats served as recipients of donor cardiac tissues obtained from 1-3 
day-old Lewis or DA rats, respectively. The two allograft groups consisted of 
adult male Lewis rats serving as recipients of either 1-3 day-old BN or DA rat 
cardiac transplants. The donor ages used have been previously reported to result 
in optimum isograft viability (Fulmer et al., 1963) and were of appropriate size so 
that whole heart grafts might be accommodated by the recipient's ear. 
Cardiac Transplantation 
The procedure utilized was a modification of the heterotopic method of 
cardiac transplantation into the mouse ear as described by Fulmer et al (1963) 
(Figure 6). Cardiac graft recipients were anesthetized with ketamine/xylazine 
(20:1) (Fort Dodge Laboratories, Fort Dodge, IA and Rugby Laboratories, Inc., 
Rockville Centre, NY) at 105 mg/kg body weight i.p. prior to surgery. The 
dorsal surface of the recipient's ear pinna was nicked at the proximal end with a 
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sterile scalpel, and a subcutaneous pouch was prepared using blunt forceps. 
Whole newborn hearts were harvested promptly at the time of donor sacrifice 
and gently inserted into the ear pouches of the recipients. In order to prevent 
graft loss and promote revascularization, skin flaps surrounding the graft site 
were apposed by applying gentle pressure with forceps. Each recipient was 
grafted bilaterally, one whole heart per recipient ear, with two isografts or two 
allografts per animal. Cardiac graft recipients were anesthetized and monitored 
from day 1 to day 10 post-tx by visual inspection for pulsatile activity and by 
electrocardiography using pin electrodes placed on either side of the graft with 
leads connected to a polygraph recorder ( Grass Instruments Model 79D, Quincy, 
MA) (Figure 7). Grafts were removed on days 1 through 10 post-tx and 












Fig. 6. Schematic diagram of the heterotopic heart graft technique used in the 
present studies. The dorsal surface of the recipient's ear pinna is nicked at the 
proximal end (1). A subcutaneous pouch is prepared to accommodate grafts (2). 
Whole newborn donor hearts are inserted into ear pouches (3). Cardiac grafts are 




Fig. 7. Illustration of physiograph recordings. Input from graft leads to 
determine graft ECG activity (a). Input from intrinsic heart leads to determine 
intrinsic heart's ECG activity (b ). 
Cell and Tissue Culture 
All cells were cultured in RPMI-1640 media supplemented with 2% 
penicillin-streptomycin, 5% L-glutamine, and 5% fetal bovine serum (Gibco, 
Grand Island, NY) at a cell density of 1 X 106 cells/ml at 37°C in a 5% CO2 
atmosphere, with the exception of the RNK-16 cell line, which was also 
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supplemented with 1 % nonessential amino acids and 5 X 10-5 M 2-B-
mercaptoethanol (Gibco ). The murine macrophage cell line P388Dl (ATCC, 
Rockville, MD), was incubated for 4 hr with 10 µg/ml LPS (Difeo, Detroit, MI) 
and used as a positive TNFa mRNA control. The rat NK cell line RNK-16 (a gift 
from Dr. C. Reynolds, NIH, Frederick, MD), was cultured for 18 hr in the 
presence of 20 ng/ ml phorbol myristate acetate (PMA) and 1000 U / ml IL-2, 
(Sigma, St. Louis, MO) and used as a negative TNFa mRNA control. Splenic 
mononuclear cells (SMNCs) were isolated as previously described (Schneider 
1984) from adult male Lewis rats and were cultured for 18 hr in the presence or 
absence of 20 ng/ml PMA and 2 µg/ml phytohemagglutinin (PHA), and used as 
postive and negative LT mRNA controls, respectively. After incubation with 
respective mitogens, cells were collected and processed for RNA as described 
below. 
RNA Blot Analysis 
For Northern blot analysis, total cellular RNA was prepared from cells 
and tissues by homogenization using a Brinkmann polytron (Brinkmann 
Instruments, Inc., Westbury, NY) in the presence of guanidinium isothiocyanate 
(Chirgwin et al., 1979). RNA was quantitated spectrophotometrically using O.D. 
260 nm determinations (Maniatis et al., 1989). After electrophoretic separation in 
a 1.0% formaldehyde agarose gel, RNA was applied by Northern transfer 
(Thomas, 1980) to Nytran filters (Schleicher & Schuell, Keene, N.H.). Filters were 
baked at 80°C for 1 hr and prehybridized in a solution containing 50% 
formamide and 10% dextran sulfate for 4 hr at 42°C. Filters were then hybridized 
overnight at 42°C in a solution containing either a TNFa cDNA probe prepared 
using the 1.7 kb murine TNFa sequence cloned into the PstI/BamHI site of 
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pUC9 vector, (a gift from Chiron Corporation, Emeryville, CA) (Pennica et al., 
1985), or an LT probe prepared using the 0.71kb Kpnl/Hincll fragment of the 
1.42 kb murine LT cDNA sequence (a gift from Dr. N. Ruddle, Yale University, 
New Haven, CT) (Li et al., 1987). Probes were radiolabeled with [32p] a-dATP as 
described elsewhere (Feinberg & Vogelstein, 1983), using the Prime-a-Gene 
labeling system (Promega, Madison, WI), and used at 2 x 106 cpm/ml of 
hybridization solution. Hybridized filters were subsequently washed at room 
temperature (2 X 15 min) in 2X SSC and 0.1 % sodium dodecyl sulfate, and then at 
55°C (2 X 15 min) in 0.2X SSC and 0.1 % sodium dodecyl sulfate, after which the 
filters were air-dried and autoradiographed using Kodak XAR-5 x-ray film with 
intensifying screens at-70° C. 
Protein Assays 
Cardiac graft tissue homogenates were prepared using a Brinkmann 
polytron (Brinkmann Instruments) in 1.5 ml phosphate-buffered saline 
containing 2 mM phenylmethylsulfonyl fluoride (PMSF) protease inhibitor 
(Sigma) for analysis of TNF protein. Tissue homogenates were briefly 
centrifuged in a microcentrifuge to remove excess particulate matter. 
Supernatants were then concentrated approximately 10-fold using Centricon-10 
microconcentrators (Amicon, Beverly, MA). The samples were kept on ice for the 
duration of the assay and subsequently stored at-70° C. Total protein levels 
were quantitated using a modification of the Lowry colorimetric procedure 
(Sigma). Tissue samples were standardized to 150 µg total protein per well and 
assayed in duplicate for TNF immunoreactive protein using an ELISA (enzyme 
linked immunosorbent assay) system containing a hamster antimouse TNFa 
antibody (Genzyme, Boston, MA). Results were analyzed 
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spectrophotometrically using a MR600 microplate reader (Dynatech 
Laboratories, Chantilly, VA) and TNF levels were expressed as pg/ml and U /ml 
± S.E.M., using recombinant mouse TNFa as the standard (Genzyme ). 
Statistical Analysis 
Experimental groups were compared using a two way analysis of 
variance for the existence of significant interaction between experimental group 
and day post-tx. Differences were considered to be statistically significant at p _::;;_ 
0.05. 
Results 
In order to determine cardiac graft viability, both isograft and allograft 
tissues were monitored daily for ECG and pulsatile activity. Representative ECG 
recordings from isografts at six different time points (days 2, 7, and 10, and at 1, 
4, and 12 months) post-tx are shown in Figure 8. Isograft tissue demonstrated 
regular and progressively stronger ECG activity when measured on days 2, 7, 
and 10 post-tx, with the average heart rate increasing by almost two-fold from 
day 2 to day 10 post-tx (Figure 8). In addition, an increase in heart rate up to one 
month post-tx was observed in isografts, at which time they tended to reach a 
steady rate of ECG activity. In isografts monitored up to 1 year post-tx, graft 
heart rate appeared to approach approximately 50% of the intrinsic heart rate of 
the animals (Figure 8). The average intrinsic heart rate of a rat was found to 
average 350 bpm, and differences in the two isograft combinations used, DA-
into-DA and Lewis-into-Lewis were not significant (data not shown). 
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In comparison, ECG recordings from cardiac allograft tissue on days 2, 7, 
and 10 post-tx demonstrated diminished electrical activity with time post-tx, 
indicating graft failure as defined by absence of detectable bpms (Figure 9). On 
day 2 post-tx, the average heart rate for allografts was 77.97 ± 10.3 bpm, which 
was not statistically significant when compared with the average isograft rate on 
the same day (Table 1). However, by day 7 post-tx the allograft rate decreased to 
64.83 ± 9.1 bpm, in contrast to an increased heart rate of 121.43 ± 16.7 observed in 
isografts. These findings represented a statistically significant difference in 
allograft heart rate on day 7 post-tx, as compared with control isografts (p _::;_ 
0.002). Isograft heart rates remained relatively constant at day 10 post-tx at 
143.14 ± 19.9, while allograft rates continued to decrease with time, such that by 
day 10 post-tx, ECG and pulsatile activity of cardiac allografts were virtually 
undetectable. In all but one case, the heart rate of allografts on day 10 post-tx 
were O bpm (Table 1). It was determined in the course of these studies that the 
average time to rejection of cardiac transplants in allograft recipients was 7 days. 
Both allograft combinations used, DA-into-Lewis and BN-into-Lewis, yielded 
similar results (data not shown). 
TABLE 1. Cardiac graft viability post-transplantation 
Allograft (bpm) 
Isograft (bpm) 
a P _::;_ 0.002 
2 
77.97 ± 10.3 
(n = 32) 
75.60 ± 9.4 
(n = 25) 
b All values except for 1 (n = 22) = 0.00. 
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Day post-TX 
64.83 ± 9.1 
(n = 29) 
121.43 ± 16.7 
(n = 21) 
10 
b 
(n = 23) 
143.14 ± 19.9 
(n = 22) 
~ 
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Fig. 8. Long-term cardiac isograft viability as determined by ECG recordings. 
Representative ECG recordings from six different time points post-tx are shown. 
All recordings were performed at a constant chart speed of 5.0 mm/ sec; bpm, 
beats per minute. 
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Fig. 9. Comparison of cardiac isograft and allograft viability. Representative 
ECG recordings from three different time points post-tx are shown. All 
recordings were performed at a constant chart speed of 5.0 mm/ sec; bpm, beats 
per minute. 
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Expression of the cytotoxic cytokine genes TNFa and LT was examined 
in cardiac transplants at various times post-tx. Cardiac graft tissue was analyzed 
for the presence of TNFa mRNA on days 1-10 post-tx by Northern blot analysis 
(Figure 10). Expression of TNFa in cardiac allografts appeared to be biphasic 
(Figure lOA). Peak levels of TNFa mRNA appeared on day 3 post-tx, and 
although levels decreased by day 4 post-tx, an increase in TNFa mRNA appeared 
again on day 6 or 7 post-tx, coinciding with graft rejection as measured by ECG 
activity (Figure 9). Detectable levels of TNFa gene expression were absent in 
RNA samples prepared from cardiac isografts (Figure lOB). 
Cardiac transplants were also analyzed for LT mRNA levels on days 1 
through 10 post-tx by Northern blot analysis (Figure 11). Similar to TNFa gene 
expression in cardiac allografts, LT demonstrated a biphasic pattern of 
expression (Figure llA). Peak levels of LT mRNA in cardiac allografts were 
observed on day 3 post-tx, with a second increase in LT transcript levels 
occurring later, coincident with graft rejection. No detectable levels of LT gene 
expression were found on days 1 through 10 post-tx in RNA samples prepared 
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Fig. lOA. TNFa mRNA levels in cardiac allografts. Total RNA isolated from 
cardiac allografts retrieved on days 1-10 post-tx were examined by Northern blot 
analysis for TNFa gene expression. Representative Northern blot is shown 
above. As with Fig. lOB, the murine monocyte cell line, P388D1, stimulated in 
vitro with LPS (10 µg/ml) for 4 hr was used as a positive TNFa mRNA control. 
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Fig. lOB. TNFa mRNA levels in cardiac isografts. Total RNA isolated from 
cardiac isografts retrieved on days 1-10 post-tx were examined by Northern blot 
analysis for TNFa gene expression. Representative Northern blot is shown 
above. The rat NK cell line, RNK-16, stimulated in vitro with a PMA (20 
ng/ml)/IL-2 (1000 U/ml) combination served as a negative control for TNFa 
mRNA expression. As with Fig. lOA, blots were prepared using 15 µg of total 
RNA per lane; autoradiogram exposure time was 18 hr. Ethidium bromide 
staining of 18S and 28S ribosomal RNA subunits is included to illustrate 
standardized lane loading and intact, nondegraded cellular RNA. Kb, kilobases. 
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Fig. llA. LT mRNA levels in cardiac allografts. Total RNA isolated from cardiac 
allografts retrieved on days 1-10 post-tx were examined by Northern blot 
analysis for LT gene expression. Representative Northern blot is shown above. 
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Fig. llB. LT mRNA levels in cardiac isografts. Total RNA isolated from cardiac 
isografts retrieved on days 1-10 post-tx were examined by Northern blot analysis 
for LT gene expression. Representative Northern blot is shown above. SMNCs 
isolated from adult male Lewis rats and stimulated in vitro with a combination of 
PMA (20 ng/ml) and PHA (2 µg/ml) for 18 hr were used as a positive control, 
and untreated SMNCs were used as a negative control for LT mRNA. As with 
Fig. 1 lA, blots were prepared using 15 µg of total RNA per lane; autoradiogram 
exposure time was 5 days. Ethidium bromide staining of 18S and 28S ribosomal 
RNA subunits is included to illustrate standardized lane loading and intact, 
nondegraded cellular RNA. Kb, kilobases. 
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In order to determine whether TNF protein levels paralleled the 
observed changes in mRNA, an ELISA method was used to quantitate TNF 
protein in transplanted cardiac tissues. TNF protein levels in cardiac allografts 
were significantly increased over cardiac isografts as early as day 2 post-tx 
(Figure 12). TNF protein demonstrated a biphasic pattern, similar to that shown 
for TNFa and LT mRNA in cardiac allograft tissues on day 3 post-tx, with 4-fold 
greater levels in allografts (approximately 400 pg/ml or 16.5 U /ml; 1 U = approx. 
24.3 pg) compared to isografts, and a second increase in TNF appeared in 
allografts on day 6 post-tx. In contrast, TNF protein levels in cardiac isografts 
were at or below standard limits of detection (50 pg/ml) at all other times post-
tx, and were significantly decreased on days 3 through 7 when compared with 
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Fig. 12. TNF protein levels in cardiac transplants. Cardiac isograft and allograft 
tissues were retrieved on days 1-10 post-tx and analyzed for TNF protein, 
expressed as pg/ml and U/ml (1 U = approx. 24.3 pg)± SEM. Data shown are 
mean values of four experiments performed with different allograft and isograft 
tissue samples. TNF protein levels in cardiac allografts were significantly 
increased when compared to cardiac isografts (p ~ 0.001). 
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Discussion 
In the present study using a heterotopic method of cardiac transplantation 
into the rat ear, we have demonstrated that cardiac allografts, but not isografts, 
undergo acute rejection by day 10 post-tx. Serial recordings of ECG activity 
indicate that the average day to rejection of cardiac allografts is Day 7 post-tx, at 
which time the average allograft heart rate has significantly decreased by two-
fold, when compared to the average heart rate of day-matched isografts. These 
findings are consistent with earlier reports assessing rat cardiac allograft rejection 
by cessation of palpable pulsatile activity (Tilney et al., 1978; Hancock et al., 1991; 
Scheringa et al., 1991). Furthermore, average allograft heart rates are found to 
continually decrease, such that by day 10 post-tx ECG activity is undetectable. In 
contrast to allograft activity, average isograft heart rates demonstrate regular 
ECG and pulsatile activity up to 1 year post-tx. Although palpable cardiac 
contractility may determine day of rejection, monitoring ECG activity allows for 
qualitative and quantitative analysis of relative graft viability. 
Rat cardiac allografts, but not isografts, indicate significant increases in 
TNFa and LT mRNA and protein levels between days 1 through 10 post-tx. We 
have found that both TNFa and LT gene expression reach peak levels in situ 
early after allografting, usually on day 3 post-tx. Levels of these cytotoxic 
cytokines decrease subsequently and rise again later post-tx, coincident with 
graft rejection. The relative contributions of TNFa and LT proteins could not be 
assessed since the TNFa antibody used in the ELISA procedure can not 
distinguish between these two cytokine proteins (Sheehan et al., 1989). Since the 
TNFa antibody was elicited using recombinant mouse TNFa (Sheenan et al., 
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1989), and results were obtained using a recombinant mouse TNFa standard, 
values of TNF protein in rat cardiac transplants reported in these studies may 
therefore be underestimated. 
Interestingly, the second increase in both TNFa and LT expression is 
consistently of lesser magnitude when compared with the first peak of 
expression, but it appears to be allograft-specific. The significance of the early 
rise in these cytotoxic cytokines post-tx is unknown. However, since this 
elevation in TNF gene expression is noted in both allograft and isograft tissues, 
we speculate that at least part of the first rise may be attributed to postsurgical 
inflammatory (i.e., nonallospecific) events. Furthermore, the significantly greater 
early TNF response noted in allografts may reflect allospecific events, such as 
endothelial cell activation (Collins et al., 1986) and increased migration and 
adhesion of leukocytes (Shalaby et al., 1985). 
These results demonstrating the presence of TNF in rat cardiac allografts 
are in accordance with recent observations reporting marked elevations in 
circulating TNFa in patients undergoing allograft rejection (Maury & Teppo, 
1987; Chollet-Martin et al., 1990), as well as in situ in allografted tissues 
(Arbustini et al., 1991; Krams 1989). Likewise, increased circulating levels of LT 
have also been detected in patients (McKenna et al., 1988; Dallman et al., 1991) 
and animal models of allograft rejection (Lowry et al., 1985b). However, our 
attempts to measure circulating levels of TNF in the transplant model used in the 
present study have consistently indicated levels at or below the limits of 
detection (50 pg/ml), even in allograft recipients. Results obtained from the 
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present study, however, indicate that both TNFa and LT levels are significantly 
elevated post-tx in allograft tissues relative to isograft controls. 
Although the present study and others report elevated levels of TNFa and 
LT during allograft rejection, the actual roles of these two cytotoxic cytokines in 
rejection are less well defined. They may participate in the rejection process by 
indirect activation of leukocyte subpopulations or by direct lytic mechanisms. 
One possible source of TNF may be activated mononuclear phagocytes in the 
heart graft, since it has been reported that TNFa is released by cells of the 
monocyte/macrophage lineage in infiltrating rejecting rat cardiac allografts 
(Lowry & Blais, 1988). Another contributing source, although possibly not the 
primary source, may be activated peripheral T lymphocytes, which have recently 
been shown to synthesize TNFa (Steffen et al., 1988). 
At least one report indicates that elevated TNF levels in serum coincides 
with clinical rejection (Maury & Teppo, 1987). The present studies, however, 
indicate significant elevations in graft TNF levels well in advance of transplant 
rejection. It has been reported that rat cardiac allografts elicit a biphasic cellular 
immune response, with the second phase coinciding with the time of acute graft 
rejection (Tilney et al., 1978); these findings are consistent with the increases in 
TNF levels observed in the present study. 
The present study supports a role for both TNFa and LT cytotoxic gene 
products in the pathogenesis of allograft rejection and indicate that elevated 
levels of TNFa/LT may act as early indicators of incipient graft rejection. Studies 
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such as these are designed to elucidate the pathophysiological mechanisms 
involved in graft rejection and may lead to more effective strategies aimed at 
promoting graft success. 
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CHAPTER3 
USE OF LOW DOSE CYCLOSPORINE A/METHOTREXATE TO PROLONG 
RAT CARDIAC ALLOGRAFT SURVIVAL 
Abstract 
CSA is the standard immunosuppressive treatment used in human 
cardiac transplantation to prevent rejection; however, adverse side effects have 
been reported at therapeutic doses. Therefore, a need remains for the 
implementation of specific therapies designed to achieve transplant success with 
a minimum of undesirable side effects. The aims of the present study were: 1) 
to evaluate the efficacy of a low dose CSA (1.0 mg/kg/ day)/ MTX (450 
µg/kg/wk) combination therapy in prolonging rat cardiac allograft survival, and 
2) to determine the effects of low dose CSA/MTX on IL-2 gene expression in rat 
cardiac allografts. The average time to rejection of newborn donor BN rat hearts 
transplanted into the ear pinnae of CSA/MTX-treated adult Lewis recipients, 
measured by the absence of ECG activity, more than doubled from day 8 post-tx 
to day 18 post-tx when compared to allografts in untreated control recipients (p ~ 
0.01). Northern blot analysis demonstrated that IL-2 mRNA transcripts in 
cardiac allografts treated with low dose CSA/MTX were detected as early as day 
1 post-tx, and at increasing levels as rejection progressed post-tx. When IL-2 
gene expression in allografts from CSA/MTX treated recipients was compared to 
levels in allografts from untreated recipients, no significant difference in the 
pattern of IL-2 induction was observed. In contrast, IL-2 mRNA transcripts were 
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not detected post-tx in allografts from recipients treated with high-dose (15 
mg/kg/ day) CSA or in cardiac isografts. The presence of IL-2 gene transcripts, 
therefore, appears to be allograft-specific. Furthermore, low dose CSA/MTX 
therapy does not appear to prolong transplant survival by altering steady-state 
levels of IL-2 gene transcripts. We conclude that low dose CSA/MTX treatment 
may serve as a possible alternative immunosuppressive therapy for promoting 
allograft survival while minimizing high dose CSA side effects. Further studies 
are required to elucidate the mechanism(s) by which low dose CSA/MTX 
combination therapy increases the time to rat cardiac allograft rejection. 
Introduction 
Using a heterotopic method of cardiac transplantation into the rat ear 
(Fulmer et al., 1963), we have previously demonstrated that cardiac allografts but 
not isografts undergo acute rejection by day 10 post-tx, with the average time to 
rejection being day 7 post-tx (Pizarro et al., 1993a). In this model, we have found 
that significant increases in TNFa and LT mRNA and protein levels occur 
between days 1 through 10 post-tx in rat cardiac allografts but not isografts 
(Pizarro et al., 1993a). These studies support a role for both TNFa and LT 
cytotoxic gene products in the pathogenesis of allograft rejection. The objective 
of the present study is to determine if a combination low CSA/MTX 
immunosuppressive therapy administered to allograft recipients has the ability 
to prolong survival of rat cardiac transplants compared to untreated controls, 
using the aforementioned model. 
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CSA is a cyclic endecapeptide derived from the soil fungus, Tolypocladium 
inflatums, and has been demonstrated to be a potent immunosuppressive agent 
and inhibitor of helper T function (Borel et al., 1976; Orosz et al., 1983). CSA was 
first introduced in human transplantation over a decade ago (Caine et al., 1978), 
and since that time has become the immunosuppressive agent of choice 
following organ replacement. Although CSA has been used with considerable 
success clinically to prolong organ graft survival (Caine et al., 1978; Costanzo-
Nordin et al., 1990), significant adverse side effects, such as nephrotoxicity 
(Myers et al., 1984), hepatotoxicity (Vine et al., 1988), hypertension (Munoz et al., 
1988), as well as neurological toxicities (deGroen et al., 1987) have been reported 
with its use. 
Since the landmark findings which first described CSA's ability to 
suppress cell-mediated immunity (Borel et al., 1976), numerous investigations 
have examined the mechanism(s) of action of CSA and have consistently 
demonstrated the inhibition of IL-2 gene transcription by CSA (Kronke et al., 
1984; Elliot et al., 1984). The main focus in attempting to elucidate CSA's 
immunosuppressive action has centered on the direct effects of CSA upon CD4 + 
helper T lymphocytes; one functional characteristic of CD4+helper T cells is the 
synthesis and subsequent release of a range of several cytokines, including IL-2. 
IL-2 has been demonstrated to induce the differentiation and clonal 
expansion of mature T lymphocytes and appears to be an important mediator of 
allograft rejection, since a positive correlation between IL-2 levels and rejection 
episodes has been described (Yoshimura & Kahan, 1985; Vie et al., 1985; 
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McKenna et al., 1988). In addition, anti-lL-2 receptor antibodies have been shown 
to prevent allograft rejection in experimental models (Kirkman et al., 1985). CSA 
is thought to act as an immunosuppressive agent through potent inhibition of IL-
2 production by T cells (Kronke et al., 1984; Elliot et al., 1984). 
Since CSA at therapeutic doses may exert profound physiologic changes 
in addition to its immunosuppressive properties, these changes often result in 
toxic side effects (Myers et al., 1984; Vine et al., 1988; Munoz et al., 1988; 
deGroen et al., 1987). Therefore, a need remains for implementing specific 
therapies directed at achieving transplant success with a minimum of 
undesirable sequelae. One approach is the utilization of combination treatments 
at lower therapeutic doses, which may result in increased survival time of organ 
transplants, while minimizing adverse side effects. 
MTX is classified pharmacologically as an antimetabolite because of its 
antagonistic effect on folic acid metabolism and function (Mitchell et al., 1969). 
MTX binds to dihydrofolate reductase which results in the inhibition of DNA 
synthesis; this antiproliferative action has made MTX a useful drug for cancer 
chemotherapy (Jolivet et al., 1983). Immunosuppressive effects have also been 
attributed to MTX (Mitchell et al., 1969), and its utilization in the treatment of 
rheumatoid arthritis, for example, has demonstrated both long term and short 
term efficacy (Weinblatt et al., 1985; Perhala & Wilke, 1991). The mechanism(s), 
however, by which MTX suppresses disease activity in inflammatory rheumatoid 
arthritis is still poorly understood and adverse side effects, such as severe 
leukopenia and gastrointestinal upset, have been associated with the use of MTX 
61 
(Weinblatt et al., 1985). It has been suggested that MTX may exert its 
immunosuppressive action by deactivation of macrophages, resulting in 
decreased IL-1 production (Hu et al., 1988), as well as by inhibition of 
macrophage migration, resulting in decreased accumulation of inflammatory 
cells and/ or immune mediators (Johnson et al., 1988). Conversely, the 
administration of MTX restored both T cell function (Kourounakis & Kapusta, 
1976) and IL-2 production (Combe et al., 1985) in rheumatoid arthritis. 
Recently, MTX has also shown favorable results in treating persistent 
mild (Olsen et al., 1990), as well as recurrent moderate to severe cardiac allograft 
rejection (Costanzo-Nordin et al., 1988). Success has also been demonstrated 
using CSA at doses of 10-15 mg/kg/ day combined with either high or low dose 
MTX in the prevention of graft-versus-host disease after bone marrow 
transplantation in experimental animal models (Deeg et al., 1982; Deeg et al., 
1984), as well as in human clinical studies (Storb et al., 1986; Truog & Wozniak, 
1990). These data strongly suggest that administration of a low dose CSA/MTX 
combination therapy may serve as a possible alternative treatment in promoting 
cardiac allograft survival while minimizing both high dose CSA and MTX side 
effects. 
The purpose of the present study was to evaluate the efficacy of low dose 
CSA (1.0 mg/kg/ day) / MTX (450 µg/kg/wk) combination therapy in 
prolonging rat cardiac allograft survival and to determine the effects of low dose 
CSA/MTX on IL-2 gene expression in rat cardiac allografts. Studies such as 
these may provide a basis for the implementation of combination 
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immunosuppressive therapies leading to improvements in post-transplantation 
management. 
Materials, Methods and Experimental Design 
Animals 
Pregnant BN and Lewis, and six to eight-week-old male Lewis rats were 
purchased from Harlan Sprague Dawley (Harlan Sprague Dawley, Indianapolis, 
IN). All animals received water and food ad libitum, and were housed in 
accordance with institutional animal care and use guidelines. Adult male Lewis 
rats served as recipients of donor cardiac tissue obtained from either one to three-
day-old Lewis or BN rats, which served as isograft and allograft groups, 
respectively. The donor ages used have been previously reported to result in 
optimum isograft viability (Fulmer et al., 1963) and were of appropriate size so 
that the whole heart grafts might be accommodated by the recipients' ears. 
Cardiac Transplantation 
The procedure utilized was a modification of the heterotopic method of 
cardiac transplantation into the mouse ear as described by Fulmer et al (1963) 
(Figure 6). Cardiac graft recipients were anesthetized with i.p. injection of 
ketamine/xylazine (20:1) (Fort Dodge Laboratories, Fort Dodge, IA and Rugby 
Laboratories, Inc., Rockville Centre, NY) at 105 mg/kg body weight prior to 
surgery. The dorsal surface of the recipient's ear pinna was nicked at the 
proximal end with a sterile scalpel and a subcutaneous pouch was prepared 
using blunt forceps. At the time of donor sacrifice, whole newborn hearts were 
harvested promptly and gently inserted into the ear pouches of the recipients. In 
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order to prevent graft loss and promote revascularization, skin flaps surrounding 
the graft site were apposed by applying gentle pressure with forceps. Each 
recipient was grafted bilaterally, one whole heart per recipient ear, with either 
two isografts or allografts per animal. Cardiac graft recipients were anesthetized 
with ketamine and monitored daily by visual inspection for pulsatile activity and 
by electrocardiography using pin electrodes placed on either side of the graft 
with leads connected to a polygraph recorder (Grass Model 79D, Grass 
Instruments Co., Quincy, MA) (Figure 7). 
Animal Treatment Groups 
Lewis cardiac allograft recipients were injected i.p. with CSA in olive oil 
vehicle once daily, beginning on the same day of transplantation (day 0), and/or 
MTX in saline vehicle once weekly, beginning one week prior to the day of 
transplantation, as follows. Allograft recipients were placed in one of five 
treatment groups consisting of either high dose CSA (15 mg/kg/ day), low dose 
CSA (1 mg/kg/ day), low dose MTX (450 µg/kg/wk), combination low dose 
CSA/MTX treatment (1 mg/kg/ day and 450 µg/kg/wk, respectively), or control 
treatment group (saline and olive oil vehicles according to the aforementioned 
protocol). All allograft recipients received treatment through day 7 post-tx. 
Cardiac transplants were monitored daily for pulsatile and ECG activity as 
described above for graft survival, with retrieval of one graft per recipient 
occurring on days 3 through 8 post-tx for each treatment group; cardiac grafts 
were processed for total cellular RNA as described below. Subsequent to these 
studies, a second treatment group consisting of low dose CSA/MTX combination 
therapy was prepared to permit graft retrieval at eight time points, days 1 
through 8 post-tx, for RNA analysis. 
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Cell Culture 
SMNCs were isolated from adult male Lewis rats by centrifugation of 
spleen tissue suspensions through a Ficoll density gradient (Lymphocyte 
Separation Medium (LSM), Organon Teknika, Durham, NC), as described in an 
earlier report (Pizarro et al., 1993a). SMNCs were cultured in RPMI-1640 medium 
supplemented with 2% penicillin-streptomycin, 5% L-glutamine and 5% fetal 
bovine serum (GIBCO, Grand Island, NY) at a cell density of 1 X 106cells/ml at 
37°C in 5% CO2 in air, either in the presence or absence of a 20 ng/ml PMA and 2 
µg/ml PHA combination for 18 hr and used as positive and negative controls for 
IL-2 mRNA, respectively. After incubation with or without mitogen stimulation, 
cells were collected and processed for RNA as described below. 
RNA Blot Analysis 
For Northern and slot blot analysis, total cellular RNA was prepared 
from cells and tissues by acid guanidinium thiocyanate-phenol-chloroform 
extraction (Chomczynski & Sacchi, 1987), and blots were prepared as described 
previously (Pizarro et al., 1993a). Filters were hybridized with an IL-2 cDNA 
probe prepared using a 900 b.p. murine IL-2 insert cloned into the BamHI site of 
pCD vector, (a gift from Dr. Ken-ichi Arai, DNAX Research Inst., Palo Alto, CA) 
(Kashima et al., 1985) and prepared for autoradiography as previously described 
(Pizarro et al., 1993a). 
Statistical Analysis 
Experimental groups were compared using analysis of variance and 
multiple regression analysis for the existence of significant differences between 
65 
treatment and control groups. Differences were considered to be statistically 
significant at p 5. 0.05. 
Results 
In order to determine cardiac graft viability, tissues transplanted in 
allograft recipients from the four experimental treatment groups (N=6) and 
control group (N=7) were monitored daily for ECG and pulsatile activity (Figure 
7). Allograft rejection was defined by the absence of detectable ECG activity. In 
untreated allograft recipients, absence of ECG activity was noted on either day 6 
or 7 post-tx in five of the seven cardiac allografts. ECG activity was undetectable 
in the two remaining grafts by day 10 post-tx; the average time to allograft 
rejection in the control group was determined to be day 7.4 ± 0.68 post-tx (Table 
2). 
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36 36 - 21-36 32.3 ± 3.75 
18 18 - 17 -18 17.8 ± 0.16 
14 12 - 12 -14 13.3 ± 0.42 
8 8 - 8-14 10.0 ± 0.89 
6 10 7 6-10 7.4 ± 0.68 
* Expired due to anesthesia complications. 
1-4N = 6 
5 N=7 
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High dose CSA-treated recipients demonstrated the longest survival time 
of cardiac allografts when compared to control and other treatment groups ( day 
32.3 ± 3.75). Figure 13 summarizes these data in graph form by depicting the 
proportion of surviving cardiac allografts in control and experimental treatment 
groups, and comparing transplant survival time (day post-tx) among the 
different groups. The incidence of death due to failure to recover from 
anesthesia administered for ECG measurements, however, was increased in the 
high dose CSA-treated group (three of the six recipients expired while under 
anesthesia during graft monitoring on days 12, 18, and 21 post-tx). Cardiac 
allograft tissue transplanted in combination low dose CSA/MTX-treated 
recipients demonstrated significantly increased survival time post-tx (average 
time to rejection was determined to be day 17.8 ± 0.16), when compared to 
untreated controls (p .5. 0.01), without apparent complications due to anesthesia 
during graft monitoring (Table 2, Figure 13). In fact, all but one (rejection by day 
17 post-tx) of the combination low dose CSA/MTX-treated recipients 
demonstrated rejection of cardiac allografts at day 18 post-tx, a two and one-half-
fold increase in allograft survival time over untreated controls. 
Furthermore, cardiac transplants in low dose CSA alone-treated recipients 
showed a significant increase in allograft survival time post-tx when compared to 
control (average time to rejection was 13.3 ± 0.42 days); however, this increase 
was found to be comparatively less than that found in heart allografts 
transplanted into low dose CSA/MTX-treated recipients (p .5. 0.05) (Table 2, 
Figure 13). Cardiac allografts in MTX alone-treated recipients did not show a 
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significant difference in graft survival time post-tx (average time to rejection was 
10.0 ± 0.89 days) compared to control (Table 2, Figure 13). 
1 ---- HIGH DOSE CSA 
c., 
z - 0.8 > --•-- CSA/MTX -> 
~ ---- LOWDOSECSA 
~ 0.6 
rJj 
z ---- MTX 
0 0.4 -E-< ---- CONTROL 
~ 
0 




0 6 10 14 17 20 24 28 32 36 
DAY POST-TX 
Fig. 13. Survival curves for cardiac allograft control and experimental treatment 
groups. All control (N=7) and treatment (N=6) groups were assessed for graft 
viability by serial ECG recordings post-tx. Allograft rejection was defined by the 
absence of detectable ECG activity. Results are reported as the proportion of 
surviving cardiac allografts in control and experimental treatment groups with 
time post-tx. Cardiac allograft survival was significantly prolonged in recipients 
treated with high dose CSA (p ~ 0.001), low dose CSA/MTX (p ~ 0.01), and low 
dose CSA (p ~ 0.05), when compared to untreated allograft recipients. 
In addition to daily monitoring of allograft viability, the intrinsic heart 
rates of control and treated recipients were also measured (Figure 7). As shown 
in Table 3, the intrinsic heart rate of all cardiac allograft recipients was 
significantly greater than graft heart rates at all times monitored, regardless of 
treatment of the recipient. The intrinsic heart rate of the recipient was found to 
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average approximately 425 bpm, with no significant differences among treatment 
groups (Table 3). 
In comparison to intrinsic heart rates, a decrease in the average heart rate 
of cardiac allografts was observed with time post-tx, which was dependent on 
the treatment given to the recipient. All cardiac allografts demonstrated similar 
heart rates up to day 3 post-tx, after which gradually diminishing as well as 
irregular ECG activity was demonstrable, indicating incipient graft rejection 
(Table 3). Allografts from untreated recipients showed more than a two-fold 
decrease in heart rate from day 3 to day 6 post-tx, from 107.14 ± 11.5 to 41.82 ± 
8.9 bpm (Table 3). As mentioned previously, absence of detectable ECG activity 
was noted on either day 6 or 7 post-tx in five of the seven untreated control 
cardiac allografts, with the two remaining grafts losing ECG activity by day 10 
post-tx (Table 2). 
Heart rates measured in cardiac allografts transplanted into low dose 
CSA/MTX-treated recipients on days 3 ,6 ,8, and 10 post-tx were found to have 
distinct and regular heart rates of 82.72 ± 8.2, 130.00 ± 20.7, 133.33 ± 15.6, and 
122.33 ± 11.6, respectively (Table 3). However, by day 14, a decrease in allograft 
heart rate (62.00 ± 19.3, Table 3) was noted in low dose CSA/MTX-treated 
recipients. A further decrease was reported with time, such that in all but one 
case, ECG and pulsatile activity were virtually undetectable by day 18 post-tx 
(Table 2). This finding, however, represented more than a two-fold increase in 
cardiac allograft survival in low dose CSA/MTX-treated recipients when 
compared to untreated controls (p ~ 0.01). 
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Graft heart rate in cardiac allografts transplanted into low dose CSA-
treated recipients decreased by day 10 post-tx (data not shown), with no 
detectable ECG activity by day 14 post-tx (Table 3). Although graft survival time 
was shorter than that found in low dose CSA/MTX-treatment, administration of 
low dose CSA alone also showed prolongation of graft survival time by almost 
one week post-tx, when compared to untreated controls (p ~ 0.05). Conversely, 
in MTX alone-treated animals, graft heart rates showed diminished ECG and 
pulsatile activity by day 6 post-tx (47.5 ± 11.1), which continued until day 10 or 
11 post-tx, at which time no detectable ECG activity was measured (Table 3). No 
statistically significant difference in allograft survival time was demonstrated in 
cardiac allografts in MTX alone-treated recipients, as compared with untreated 
controls. 
Cardiac allografts in high dose CSA-treated recipients showed regular but 
gradually diminishing heart rates through day 29 post-tx, at which time the 
remaining three allografts demonstrated markedly diminished heart rates (Table 
3, Figure 13); graft failure was noted by day 36, when no detectable ECG and 














TABLE 3. Cardiac heart rate post-transplant 
DAY3 DAY6 DAYS 
GRAFT INTRINSIC GRAFT INTRINSIC GRAFT INTRINSIC 
RATE' RATE RATE RATE RATE RATE 
85.00 400.00 130.00 406.67 155.00 430.00 
+9.6 ± 11.5 ±18.3 ±29.6 ± 12.6 ±.25.2 
82.72 457.70 130.00 412.50 133.33 490.00 
+ 8.2 ±21.7 +20.7 ± 12.5 +15.6 +29.2 
90.00 433.00 125.00 376.66 122.50 426.66 
±12.9 ±24.0 ±18.5 ±43.3 ±6,3 ± 17.6 
67.50 466.67 47.50 426.67 24.28 483.33 
±14.9 ±24.0 ±11.1 ± 17.6 ±9.0 ±37.6 
107.14 400.00 41.82 420.00 * 446.67 











INTRINSIC GRAFT INTRINSIC 
RATE RATE RATE 
428.00 92.50 365.00 
±21.5 ± 16.5 ±23.6 






* No detectable ECG activity 










2 For all treatment groups, N = number at Day 3 post-tx 
Representative ECG recordings from cardiac allograft tissue from control 
and experimental treatment groups at nine different time points (days 3, 6, 8, 10, 
12, 14, 18, 29, and 36) post-tx are shown in Figure 14. Diminished electrical 
activity with time post-tx was observed for transplanted cardiac allografts by day 
8 in untreated control recipients, day 10 in MTX alone-treated recipients, day 14 
in low dose CSA alone-treated recipients, day 18 in combination low dose 
CSA/MTX-treated recipients, and day 36 in high dose CSA-treated recipients. 
Diminished ECG and pulsatile activity, as well as a decrease in the amplitude 
and regularity of heart rates, occurred a few days prior to actual rejection 
indicating impending graft failure. 
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Fig. 14. Comparison of cardiac allograft viability in treated and untreated 
recipients. Representative ECG recordings from nine different time points (day 
3, 6, 8, 10, 12, 14, 18, 29, and 36) post-tx are shown (A on this page, B, and Con 
the following pages). All recordings were performed at a constant chart speed of 
5.0 mm/ sec; bpm, beats per minute. 
73 
Day 10 Day 12 Day 14 
140 bpm 150 bpm 110 bpm 
High Dose CSA 1 
70 bpm 
CSA/MTX ND. 
80 bpm 30 bpm 0 bpm 






Day 18 Day 29 Day 36 
90 bpm 35 bpm 0 bpm 






IL-2 mRNA levels were examined in cardiac allografts from untreated 
control recipients and combination low dose CSA/MTX-treated recipients at 
various times post-tx. IL-2 mRNA levels were also examined in cardiac isografts 
transplanted into untreated recipients. Northern blot analysis of IL-2 gene 
expression in untreated cardiac allografts appeared to increase with time post-tx 
(Figure 15A). Although detectable transcripts were observed as early as day 1 or 
day 2 post-tx, a significant increase in IL-2 mRNA levels appeared on day 3 post-
tx, as well as on days 7 and 8 post-tx, at which time graft rejection usually occurs 
(Table 2, Figure 15A). IL-2 mRNA levels were also examined on days 1 through 8 
post-tx in cardiac allografts transplanted into combination low dose CSA/MTX-
treated recipients (Figure 15B). Similar to IL-2 gene expression in cardiac 
allografts from untreated control recipients, IL-2 transcripts in low dose 
CSA/MTX-treated cardiac allografts were detected at early times post-tx, with 
increased IL-2 mRNA levels by day 3 post-tx. These levels of IL-2 mRNA 
remained high, with the exception of day 6, through day 8 post-tx, coincident 
with graft rejection in untreated allograft recipients. In contrast to untreated and 
low dose CSA/MTX-treated allografts, Northern blot analysis of cardiac isografts 
did not demonstrate detectable levels of IL-2 mRNA on days 1 through 8 post-tx 
(Figure 15C). Similarly, IL-2 gene transcripts were not detected in rat cardiac 
allografts transplanted into high dose CSA-treated recipients (Figure 15D). 
However, no apparent differences, including a decrease in IL-2 transcript levels 
on day 6 post-tx, were seen at the steady state level of IL-2 mRNA in rat cardiac 
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Fig. 15A. IL-2 mRNA levels in cardiac allografts transplanted into untreated 
control recipients. Total RNA isolated from cardiac a'llografts retrieved on days 
1-8 post-tx were examined by Northern blot analysis for IL-2 gene expression. 
Representative Northern blot is shown above. As with Fig. 14B, 14C, and 14D, 
blots were prepared using 15 µg of total RNA per lane; autogradiogram exposure 
time was 18 hr. Ethidium bromide staining of 18S and 28S ribosomal RNA 
subunits is included to illustrate standardized lane loading and intact, non 
degraded cellular RNA. Kb, kilobases. 
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Fig. 15B. IL-2 mRNA levels in cardiac allografts transplanted into low dose 
CSA/MTX-treated recipients. Total RNA isolated from cardiac allografts 
retrieved on days 1-8 post-tx were examined by Northern blot analysis for IL-2 
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Fig. 15C. IL-2 mRNA levels in cardiac isografts transplanted into untreated 
control recipients. Total RNA isolated from cardiac isografts retrieved on days 1-
8 post-tx were examined by Northern blot analysis for IL-2 gene expression. 
Representative Northern blot is shown above. 
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Fig. 15D. IL-2 mRNA levels in cardiac allografts transplanted into high dose 
CSA-treated recipients. Total RNA isolated from cardiac allografts retrieved on 
days 3-8 and 36 post-tx were examined by Northern blot analysis for IL-2 gene 
expression. Representative Northern blot is shown above. Blot was 
subsequently stripped and reprobed for GAPDH housekeeping gene expression 
l.3Kb, (middle panel). 
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Discussion 
Both beneficial as well as adverse effects of CSA have been well 
documented since its initial use as a potent immunosuppressive agent in clinical 
transplantation (Caine et al., 1978). Adverse side effects, in particular 
nephrotoxicity (Myers et al., 1984) and hepatotoxicity (Vine et al., 1988), have 
restricted its use at therapeutic doses (between 10-15 mg/kg/ day) and have 
initiated attempts into exploring combination low-dose therapies. In fact, 
concurrent administration of CSA with azathioprine, corticosteroids, polyclonal 
antilymphocyte globulins, and monoclonal antibodies, such as OKT3, are 
combination immunosuppressive regimens currently used in patients to promote 
cardiac allograft survival (McGoon & Frantz, 1992). However, along with CSA, 
the aforementioned immunosuppressive agents when administered at 
therapeutic doses, also possess side effects with potentially undesirable 
consequences (McGoon & Frantz, 1992). 
Immunosuppressive properties have been attributed to the 
chemotherapeutic drug, MTX (Mitchell et al., 1969; Weinblatt et al., 1985; Perhala 
& Wilke, 1991). High dose MTX has long been used for treatment of neoplastic 
diseases and works by indirectly inhibiting DNA synthesis (Jolivet et al., 1983). 
The primary clinical concern with the administration of therapeutic doses of 
MTX (conventionally 10 mg/every other day), is bone marrow suppression, 
which may result in leukopenia as well as initiate the impending risk of infection 
(Weinblatt et al., 1985). Low dose MTX has been also used in the treatment of 
rheumatoid arthritis and its efficacy appears to depend on immunosuppressive 
activities (Weinblatt et al., 1985; Perhala & Wilke, 1991). Recently, low dose MTX 
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has also been used in patients to control persistent mild, as well as recalcitrant 
cardiac allograft rejection (Costanzo-Nordin et al., 1988), and in canine recipients 
to prevent rejection of pulmonary allografts (Blumenstock et al., 1988). Therefore, 
low dose MTX treatment (450 µg/kg/wk in the present study), maintains 
immunosuppressive efficacy and has a markedly lower incidence of toxicity. 
The present study, using a heterotopic method of cardiac transplantation 
into the rat ear, has indicated that low dose CSA/MTX treatment, where average 
day to rejection is day 18 post-tx, significantly prolonged cardiac allograft 
survival over day-matched allografts transplanted into untreated control 
recipients, where average day to rejection is day 7 post-tx. Treatment of cardiac 
allograft recipients with combination low dose CSA/MTX immunosuppressive 
therapy, therefore, more than doubled allograft survival time post-tx when 
compared to untreated controls. No apparent complications due to anesthesia 
administration at the time of cardiac monitoring were noted in this treatment 
group, in contrast to high dose CSA-treated recipients. Contrary to cardiac 
allograft viability, average isograft heart rates were previously shown to possess 
regular ECG and pulsatile activity up to one year post-tx (Pizarro et al., 1993a). 
The present study also showed that combination low dose CSA/MTX 
treatment significantly increased graft survival compared to low dose CSA alone 
as well as MTX alone-treatments. Cardiac allografts transplanted into MTX 
alone-treated recipients did not show significant differences in graft survival 
time post-tx when compared with allografts from untreated recipients. Although 
cardiac allografts transplanted into low dose CSA-treated recipients 
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demonstrated an increase in transplant survival time over untreated controls (p .$. 
0.05), this increase was found to be less than that found in combination low dose 
CSA/MTX-treated recipients (p .$. 0.01). 
Low dose CSA treatment (2.0 mg/kg/ day) of allograft recipients reduces 
T cell proliferative responsiveness, but is unable to sustain long-term cardiac 
allograft survival (Stepkowski et al., 1989). Studies such as these suggest that low 
dose CSA administration has the ability to prolong cardiac graft survival post-tx, 
by activation of T cell suppressor function(s) and/ or by altering the T cell's 
ability to proliferate. The present studies indicate that low dose CSA treatment, 
while able to delay allograft rejection, does not have the efficacy of combination 
low dose CSA/MTX in prolonging rat cardiac allograft survival. The possibility 
exists that MTX may provide additional immunosuppressive capabilities by 
affecting T cell function and/ or regulating other cells participating in the 
immune response. 
Although the mechanism(s) by which MTX appears to exert 
immunosuppression is still poorly understood, it is believed that MTX may 
possess primarily anti-inflammatory activity due to rapidly occurring palliative 
effects (Weinblatt et al., 1985). Indeed, animal studies support an anti-
inflammatory mechanism of action for MTX. In a murine model of adjuvant-
induced arthritis, MTX inhibited hind paw edema, the activation of macrophages 
by PGE2, the influx of MHC class II and macrophages into synovial tissue, and 
IL-1 production (Hu et al., 1988). The findings that low dose MTX prevents 
occurrence of arthritis induced by Freund's adjuvant in the rat, but fails to inhibit 
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cyclo-oxygenase or 5-lipoxygenase, has been interpreted as evidence for 
immunomodulation (Stepkowski et al., 1989). Furthermore, production of IL-1 
and induction of primary delayed-type hypersensitivity were inhibited in MTX-
treated rodents (Hu et al., 1988; Gibbons & Lucas, 1989). Therefore, in the 
present study, the possibility exists that significant prolongation of cardiac 
allografts transplanted into combination low dose CSA/MTX-treated recipients 
may be due, in part, to the combined immunosuppressive actions of low dose 
CSA primarily at the T cell level and MTX primarily at the macrophage effector 
cell level. 
In the present study, IL-2 mRNA levels in cardiac tissue was examined to 
determine whether combination low dose CSA/MTX treatment, like high dose 
CSA therapy, exerts its immunosuppressive action by altering steady state levels 
of IL-2 mRNA. IL-2 gene transcripts were not detected in isografts or in rat 
cardiac allografts transplanted into high dose CSA-treated recipients on any day 
post-tx, when compared to allografts from untreated recipients. These findings 
support previous reports that treatment with high dose CSA suppresses IL-2 
gene transcription (Kronke et al., 1984; Elliot et al., 1984). No apparent 
differences in IL-2 mRNA transcript levels were observed, however, between rat 
cardiac allograft tissues transplanted into untreated and low dose CSA/MTX-
treated recipients. IL-2 gene expression occurred early during the rejection 
process, with IL-2 transcripts detected as early as day 1 or day 2 post-tx in heart 
tissues transplanted in both low dose CSA/MTX-treated and untreated 
recipients. Peak levels of IL-2 mRNA in cardiac allografts appeared early after 
transplant, usually by day 3 post-tx, in both treated and untreated recipients. IL-
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2 mRNA levels remained elevated through day 8 post-tx, by which time allograft 
rejection occurs in untreated recipients, as measured by the absence of detectable 
ECG and pulsatile activity. 
The present study reports an increased efficacy of low dose CSA/MTX 
combination therapy in prolonging rat cardiac allograft survival when compared 
to low dose CSA alone, low dose MTX alone, as well as untreated control 
recipients. Unlike high dose CSA therapy, the mechanism(s) by which low dose 
CSA/MTX prolongs allograft survival does not appear to be mediated by the 
inhibition of IL-2 gene transcription. The possibility exists that low dose 
CSA/MTX combination therapy may act on different effector cell populations 
engaged in the allogeneic immune response. Further studies must address the 
effects of low dose CSA and low dose MTX treatment alone on T-cell and 
macrophage cytokine gene expression in rat cardiac allografts. Studies such as 
these may provide new insight into the mechanisms of action of combination 




LOW DOSE CYCLOSPORINE A/METHOTREXATE COMBINATION 
THERAPY LOWERS CYTOTOXIC GENE EXPRESSION IN RAT CARDIAC 
TRANSPLANTS 
Abstract 
We have previously shown that administration of a combination 
low dose CSA (1.0 mg/kg/ day) / MTX (450 µg/kg/wk) treatment significantly 
increases the survival of rat cardiac allografts, and may therefore potentially 
serve as an alternative immunosuppressive therapy designed to promote 
transplant survival while minimizing high dose CSA side effects. In contrast to 
high dose CSA, low dose CSA/MTX treatment does not appear to alter IL-2 gene 
expression, since similar patterns of IL-2 gene transcripts were found in both low 
dose CSA/MTX-treated and untreated control allografts on Days 1 through 8 
post-tx. The mechanism(s) by which low dose CSA/MTX therapy increases the 
time of allograft survival remains to be elucidated. The aim of the present study 
was to determine the effects of low dose CSA/MTX on the expression of the 
cytotoxic cytokines, TNFa, LT, and the serine proteases HF and Cll (granzymes 
A and B, respectively) in rat cardiac allografts during rejection. RNA blot 
analysis showed significant suppression of TNFa, LT, HF, and Cll gene 
expression on days 1 through 8 post-tx in cardiac allografts from low dose 
CSA/MTX-treated recipients compared to untreated allograft controls. TNF 
protein levels in cardiac allografts from low dose CSA/MTX-treated recipients 
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were also found to be significantly reduced on days 1 through 8 post-tx when 
compared to time-matched untreated allograft controls (p ~ 0.001). We conclude 
that low dose CSA/MTX treatment, while effective in prolonging cardiac 
transplant survival, appears to act at the mRNA level to downregulate cytotoxic 
gene expression. Such trials aimed at evaluating low-dose combination therapy 
may afford new insight into mechanisms underlying improvement in 
immunosuppressive treatment. 
Introduction 
We have previously shown that low doses of both CSA and MTX, when 
used in combination, significantly increases the survival of rat cardiac allografts 
(Pizarro et al., 1993b) and therefore may serve as an alternative 
immunosuppressive therapy directed at promoting transplant survival. In 
contrast to high dose CSA administration, combination low dose CSA/MTX 
treatment does not appear to effect IL-2 gene expression. Similar levels of IL-2 
gene transcripts have been found in cardiac allografts from both low dose 
CSA/MTX-treated and untreated transplant recipients on Days 1 through 8 post-
tx (Pizarro et al., 1993b). In addition, significant increases in TNFa and LT 
mRNA and protein levels have been shown to occur between days 1 through 10 
post-tx in rat cardiac allografts transplanted into untreated recipients (Pizarro et 
al., 1993a), supporting a role for both TNFa and LT in the pathogenesis of 
allograft rejection. The need remains, therefore, to determine the mechanism(s) 
by which low dose CSA/MTX combination therapy increases allograft survival 
time compared to controls. 
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After transplantation of a tissue allograft, an infiltrate consisting of several 
cell phenotypes appears within the graft (Hanto et al., 1982). Both helper and 
cytotoxic T lymphocyte infiltration precede the destruction of the transplanted 
tissue by several days, and it is believed that these cells are paramount in the 
process of allograft rejection (Loveland & McKenzie, 1982; Lowry et al., 1983). 
Macrophages and NK cells have also been found to be components of the cellular 
infiltrate in organ allografts undergoing acute rejection (Strom et al., 1977; 
MacPherson & Christmas, 1984; Nemlander et al., 1983). These cells proliferate 
and release cytokines which have been shown to damage blood vessels within 
the graft (Dvorak et al., 1980), cause an increase in graft infiltration by leukocytes 
(Cox et al., 1984), and stimulate the differentiation of graft-specific T cells at the 
graft site (Heidecke et al., 1984). These local events mediated, at least in part, by 
cytokines contribute to allograft damage and eventual rejection of the 
transplanted tissue. 
TNFa and LT are two closely related cytokines which are endogenous 
mediators of immunological and inflammatory events. TNFa and LT share 36% 
and 51 % structural homology in overall nucleotide and amino acid sequences, 
respectively (Pennica et al., 1984), appear to have common receptor binding 
domains (Aggarwal et al., 1985a), and also exert similar immunological effects in 
vitro (Beutler & Cerami, 1986; Beutler, 1990). With regard to transplant 
rejection, elevated levels of TNFa have been reported during rejection of rat 
cardiac allografts (Lowry & Blais, 1988) as well as in human renal and liver 
allografts (Maury & Teppo, 1987; Imagawa et al., 1990a). Additionally, enhanced 
cytotoxic activity, attributed to LT, has been reported during renal allograft 
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rejection (Hancock et al., 1991; Moy & Rosenau, 1981). We have recently 
demonstrated elevated biphasic patterns for both TNFa and LT gene expression 
post-tx in rat cardiac allografts (Pizarro et al., 1993a). This allospecific increase in 
TNF levels noted within the first few days post-tx may act as an early indicator of 
graft rejection. Furthermore, recent studies have reported successful use of anti-
TNFa and LT antibodies in prolonging the survival of transplanted grafts in 
experimental animals, indicating a contribution of TNF in mediating acute 
rejection (lmagawa et al., 1990b; Scheringa et al., 1991; Teramoto et al., 1991). 
These data strongly suggest a role for TNFa and/or LT as putative effector 
molecules in allograft rejection. 
Cytotoxic T lymphocytes are believed to be important effector cells in the 
destruction of transplanted tissue during allograft rejection (Loveland & 
McKenzie, 1982; Lowry et al., 1983). Cytotoxic T cells recognize alloantigens on 
the surface of MHC-nonidentical target cells, bind to them, and induce target cell 
lysis (Hall et al., 1978). Although various steps in this process have been 
analyzed in considerable detail, most studies have not provided insight into the 
mechanism(s) by which the killer cell administers the "lethal hit" to the target cell. 
Recently, two genes encoding the serine esterases HF and Cl 1 (Granzymes A and 
B, respectively), which are selectively expressed in cytotoxic cells including 
cytotoxic T lymphocytes and NK cells, have been cloned (Gershenfeld & 
Weissman, 1986; Lobe et al., 1986). The kinetics of HF and C11 gene expression 
closely parallel the cytolytic responses in vitro (Gershenfeld & Weissman, 1986; 
Lobe et al., 1986), in that the observed kinetics of serine esterase release and of the 
delivery of the lethal hit are consistent with the hypothesis that both events occur 
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simultaneously. There exists, therefore, a strong correlation between granzyme 
gene expression and cytotoxic potential. Detection of transcripts encoding 
cytotoxic T cell serine proteases have been recently described in situ during 
murine cardiac allograft rejection (Mueller et al., 1988). These data would 
therefore suggest that cytotoxic cell-specific serine proteases, HF and Cl 1, may 
play a role in the pathogenesis of rat cardiac allograft rejection. 
The objectives of this study were to assess the degree of expression of the 
genes encoding the serine proteases, HF and Cll, during rat cardiac allograft 
rejection and to determine the effects of a combination low dose CSA/MTX 
therapy on the expression of TNFa and LT, as well as HF and Cll, during 
rejection. We report herein that combination low dose CSA/MTX 
immunosuppressive treatment of rat cardiac recipients significantly decreases 
TNFa, LT, HF, and Cll gene expression on days 1 through 8 post-tx in 
transplanted allografts when compared to allografts retrieved from untreated 
control recipients. Therefore, low dose CSA/MTX therapy prolongs cardiac 
transplant survival and appears to act at the transcriptional level to 
downregulate cytotoxic cytokine gene expression. Studies of cytotoxic cytokine 
gene expression during allograft rejection may aid in the development of more 
specifically targeted immunosuppressive therapies designed to prolong graft 
survival. 
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Materials and Methods 
Animals 
Pregnant BN and Lewis, and 6 to 8-week-old male Lewis rats were 
purchased from Harlan Sprague Dawley (Harlan Sprague Dawley, Indianapolis, 
IN). All animals received water and food ad libitum, and were housed in 
accordance with institutional animal care and use guidelines. Adult male Lewis 
rats served as recipients of donor cardiac tissue obtained from either 1 to 3 day-
old Lewis or BN rats, which served as isograft and allograft groups, respectively. 
The donor ages used have been previously reported to result in optimum isograft 
viability (Fulmer et al., 1963) and were of appropriate size so that whole heart 
grafts might be accommodated by the recipients' ears. 
Cardiac Transplantation 
The procedure utilized was a modification of the heterotopic method of 
cardiac transplantation into the mouse ear as described by Fulmer et al (1963) 
(Figure 6). Cardiac graft recipients were anesthetized with an i.p. injection of 
ketamine/xylazine (20:1) (Fort Dodge Laboratories, Fort Dodge, IA and Rugby 
Laboratories, Inc., Rockville Centre, NY) at 105 mg/kg body weight prior to 
surgery. The dorsal surface of the recipient's ear pinna was nicked at the 
proximal end with a sterile scalpel and a subcutaneous pouch was prepared 
using blunt forceps. Whole newborn hearts were harvested promptly at the time 
of donor sacrifice and gently inserted into the ear pouches of the recipients. In 
order to prevent graft loss and promote revascularization, skin flaps surrounding 
the graft site were apposed by applying gentle pressure with forceps. Each 
recipient was grafted bilaterally, one whole heart per recipient ear, with either 
two isografts or allografts per animal. Cardiac graft recipients were anesthetized 
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and monitored daily by visual inspection for pulsatile activity and by 
electrocardiography using pin electrodes placed on either side of the graft with 
leads connected to a polygraph recorder (Grass Model 79D, Grass Instruments 
Co., Quincy, MA) (Figure 7). 
Animal Treatment Groups 
Lewis cardiac allograft recipients were injected i.p. with CSA in olive oil 
vehicle once daily, beginning on the same day of transplantation, and/or MTX in 
saline vehicle once weekly, beginning 1 week prior to the day of transplantation 
(day 0), as follows. Allograft recipients were placed in one of five treatment 
groups consisting of either high dose CSA (15 mg/kg/ day), low dose CSA (1 
mg/kg/ day), low dose MTX (450 µg/kg/wk), combination low dose CSA/MTX 
treatment (1 mg/kg/ day and 450 µg/kg/wk, respectively), or control treatment 
group (saline and olive oil vehicles according to the aforementioned protocol). 
All allograft recipients received treatment through day 7 post-tx. Cardiac 
transplants were monitored daily for pulsatile and ECG activity as described 
above for graft survival, with retrieval of one graft per recipient occurring on 
days 1-8 post-tx for each treatment group; cardiac grafts were processed for RNA 
blot analysis as described below. Subsequent to these studies, a second treatment 
group consisting of low dose CSA/MTX combination therapy was prepared to 
permit graft retrieval at eight time points, days 1-8 post-tx. 
Cell Culture 
All cells were cultured in RPMI-1640 media supplemented with penicillin-
streptomycin (100 U/ml and 100 µg/ml, respectively), 2 mM L-glutamine and 
5% fetal bovine serum (GIBCO, Grand Island, NY) at a cell density of 1 X 106 
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cells/ml at 37°C in 5% C02J with the exception of the RNK-16 cell line which was 
also supplemented with 1 % nonessential amino acids and 5 X 10-5 M 2-~-
mercaptoethanol (GIBCO). The murine macrophage cell line, ANA-1 (a gift from 
Dr. Luigi Varesio, NIH, Frederick, MD), was incubated for 4 hr with 10 µg/ml 
LPS (Difeo, Detroit, MI), and used as a positive TNFa mRNA control. The rat 
NK cell line, RNK-16 (a gift from Dr. C.W. Reynolds, NIH, Frederick, MD), was 
cultured for 18 hr in the presence of 20 ng/ml PMA and 1000 U /ml IL-2, (Sigma 
Chemical Co., St. Louis, MO), and used as a negative TNFa mRNA control. 
SMNCs isolated from adult male Lewis rats as described previously (Pizarro et 
al., 1993a), were cultured for 18 hr with or without a combination of 20 ng/ml 
PMA and 2 µg/ml PHA, and used as positive and negative controls, respectively, 
for LT and granzyme mRNA expression. After incubation with respective 
mitogens, cells were collected and processed for RNA as described below. 
RNA Blot Analysis 
For Northern and slot blot analysis, total cellular RNA was prepared 
from cells and tissues by acid guanidinium thiocyanate-phenol-chloroform 
extraction (Chomczynski & Sacchi, 1987), and blots were prepared as described 
previously (Pizarro et al., 1993a). Filters were hybridized overnight at 42°C in a 
solution containing either a TNFa cDNA probe prepared using the 1.7 kb murine 
TNFa sequence cloned into the Pstl/BamHI site of pUC9 vector, (a gift from the 
Chiron Corp., Emeryville, CA) (Pennica et al., 1985), an LT probe prepared using 
a 0.71kb Kpnl/Hincll insert of the 1.42 kb murine LT cDNA fragment cloned into 
the EcoRI/BamHI site of pBR322 vector (a gift from Dr. N. Ruddle, Yale 
University, New Haven, CT) (Li et al., 1987), an HF probe synthesized from a 950 
b.p. murine HF cDNA fragment cloned into the EcoRI site of pBS KS- vector (a 
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gift from Dr. I. Weissman, Stanford University School of Medicine, Palo Alto, 
CA) (Gershenfeld & Weissman, 1986), or a murine Cll probe prepared using an 
800 b.p. Cl 1 cDNA sequence cloned into the EcoRI/BamHl site of pGEM3Z 
vector (a gift from Dr. R.C. Bleackley, University of Alberta, Edmonton, ALB) 
(Lobe et al., 1986), and prepared for autoradiography as described in an earlier 
report (Pizarro et al., 1993a). Relative quantitation of mRNA signals on slot blot 
autoradiographs were measured by transmission densitometry (Model EC910, E-
C Apparatus, Corp., St. Petersburg, FL) and reported as arbitrary units 
representing integrated areas of densitometric tracings. 
Protein Assays 
Cardiac graft tissue homogenates were prepared using a Brinkmann 
polytron (Brinkmann Instruments, Inc.) in 1.5 ml phosphate buffered saline 
containing 2 mM PMSF protease inhibitor (Sigma Chemical Co.) for analysis of 
TNF protein. Tissue homogenates were briefly centrifuged in a microcentrifuge 
to remove excess particulate matter. Supernatants were then concentrated 
approximately 10-fold using Centricon-10 microconcentrators (Amicon, Beverly, 
MA). The samples were kept on ice for the duration of the assay and 
subsequently stored at -70° C. Total protein levels were quantitated using a 
modification of the Lowry colorimetric procedure (Sigma Diagnostics, St. Louis, 
MO). Tissue samples were standardized to 150 µg total protein per well and 
assayed in duplicate for TNF immunoreactive protein in an ELISA system using 
a hamster anti-mouse TNF antibody (Genzyme Corp., Boston, MA), which 
recognizes both mouse TNFa and LT. Results were analyzed 
spectrophotometrically using a MR600 microplate reader (Dynatech 
Laboratories, Inc., Chantilly, VA) and TNF levels were expressed as pg/ml and 
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U /ml± SEM, relative to a recombinant mouse TNFa standard (Genzyme Corp., 
Boston MA). 
Statistical Analysis 
Experimental groups were compared using analysis of variance and 
multiple regression analysis for the existence of significant differences between 
treatment and control groups. Differences were considered to be statistically 
significant at p ~ 0.05. 
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Results 
Cardiac allograft tissues were serially monitored for ECG and pulsatile 
activity in order to determine graft viability post-tx. Allograft rejection was 
defined by the absence of detectable ECG activity. The average time to allograft 
rejection of cardiac transplants in untreated control recipients was determined to 
be Day 7.4 ± 0.68 post-tx, with absence of detectable ECG and pulsatile activity 
noted in all untreated control allografts by Day 10 post-tx (Pizarro et al., 1993a; 
Pizarro et al., 1993b ). 
Combination low dose CSA/MTX-treated recipients demonstrated a two 
and one-half fold increase in survival time post-tx of transplanted cardiac 
allografts when compared to cardiac allografts transplanted into untreated 
control recipients (p ~ 0.01) (Pizarro et al, 1993b ). Cardiac transplants in low dose 
CSA alone-treated recipients also demonstrated a less, but significant increase in 
allograft survival time when compared to control (p ~0.05), while no statistically 
significant difference in cardiac allograft survival times post-tx between MTX-
alone and untreated recipient groups were found (Pizarro et al., 1993b). Cardiac 
allograft survival time post-tx in high dose CSA-treated recipients represented 
the longest survival time of the four treatment groups; however, the incidence of 
anesthesia-related death was increased in this experimental group (Pizarro et al., 
1993b). 
Expression of the cytotoxic cytokine genes, TNFa and LT, was examined 
in cardiac allografts transplanted into untreated control and combination low 
dose CSA/MTX-treated recipients on days 1 through 8 post-tx. As shown in 
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Figure 16, cardiac graft tissues were analyzed for the presence of TNFa mRNA 
by Northern blot analysis. Expression of TNFa in cardiac allografts from 
untreated control recipients appeared to be biphasic (Figure 16A). Peak levels of 
TNFa mRNA appeared on day 3 post-tx, and although levels decreased by day 4 
post-tx, an increase in TNFa mRNA appeared again on day 6 (5/10) or 7 (3/10) 
post-tx, coinciding with graft rejection as measured by ECG activity. TNFa 
transcript levels appeared to be significantly decreased in allograft heart tissues 
from combination low dose CSA/MTX-treated recipients when compared to 
untreated recipients on all days assayed post-tx (Figure 16B). Although TNFa 
transcript levels were significantly decreased in cardiac allografts from 
CSA/MTX-treated animals, these samples also indicated a biphasic pattern of 
TNFa expression with time post-tx. Similar to untreated control allografts, an 
increase in TNFa transcripts was detected on day 3 post-tx, and again just prior 
to rejection in low dose CSA/MTX-treated allografts (Figure 16B). TNFa 
transcript levels were undetectable in cardiac isografts on days 1-8 post-tx 
(Pizarro et al., 1993a). 
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Fig. 16A. TNFa mRNA levels in cardiac allografts transplanted into untreated 
control recipients. Total RNA isolated from cardiac allografts retrieved on days 
1-8 post-tx were examined by Northern blot analysis for TNFa gene expression. 
A Representative Northern blot is shown above. As with Fig. 16 B, the murine 
monocyte cell line, ANA-1, stimulated in vitro with LPS (10 µg/ml) for 4 hr was 
used as a positive TNFa mRNA control, while the rat NK cell line, RNK-16, 
stimulated in vitro with a PMA (20 ng/ml)/IL-2 (l000U/ml) combination served 
as a negative control for TNFa mRNA expression. Kb, kilobases. 
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Fig. 16B. TNFa mRNA levels in cardiac allografts transplanted into low dose 
CSA/MTX-treated recipients. Total RNA isolated from cardiac allografts on 
days 1-8 post-tx were examined by Northern blot analysis for TNFa gene 
expression. Representative Northern blot is shown above. As with Fig. 16A, 
blots were prepared using 15 µg of total RNA per lane; autogradiogram exposure 
time was 18 hr. Ethidium bromide staining of 18S and 28S ribosomal RNA 
subunits is included to illustrate standardized lane loading and intact, non 
degraded cellular RNA. 
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Fig. 17A. LT mRNA levels in cardiac allografts transplanted into untreated 
control recipients. Total RNA isolated from cardiac allografts retrieved on days 
1-8 post-tx were examined by Northern blot analysis for LT gene expression. 
Representative Northern blot is shown above. As with Fig. 17B, SMNCs isolated 
from adult male Lewis rats and stimulated in vitro with a combination of PMA 
(20 ng/ml) and PHA (2 µg/ml) for 18 hr were used as a positive control, and 
untreated SMNCs were used as a negative control for LT mRNA expression. 
SMNCs, spleen mononuclear cells; Kb, kilobases. 
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Fig. 17B. LT mRNA levels in cardiac allografts transplanted into low dose 
CSA/MTX-treated recipients. Total RNA isolated from cardiac allografts 
retrieved on days 1-8 post-tx were examined by Northern blot analysis for LT 
gene expression. Representative Northern blot is shown above. As with Fig. 
17 A, blots were prepared using 15 µg of total RNA per lane; autogradiogram 
exposure time was 5 days. Ethidium bromide staining of 18S and 28S ribosomal 
RNA subunits is included to illustrate standardized lane loading and intact, non 
degraded cellular RNA. 
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Cardiac allograft transplants from untreated and low dose CSA/MTX-
treated recipients were also analyzed for LT mRNA levels on days 1 through 8 
post-tx by Northern blot analysis (Figure 17). Similar to TNFa, LT demonstrated 
a biphasic pattern of gene expression in allografted heart transplants from 
untreated recipients (Figure 17A). Peak levels of LT mRNA in untreated cardiac 
allografts were observed on day 3 post-tx, with a second increase in LT transcript 
levels occurring later, coincident with graft rejection. In contrast, LT mRNA 
levels were significantly reduced in low dose CSA/MTX-treated cardiac 
allografts when compared to untreated controls (Figure 17B); low to undetectable 
levels of LT transcripts were found in low dose CSA/MTX-treated allografts on 
Days 1 through 8 post-tx (Figure 17B). Similar patterns of TNFa and LT mRNA 
levels were observed in slot blot analysis (Figure 18A and 18B), where all cardiac 
allograft RNA samples were exposed to identical hybridization and 
autoradiography conditions, with different exposure times. LT mRNA levels 
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Fig. 18. Densitometric measurement of TNFa and LT transcript levels from 
representative slot blots of cardiac allograft total cellular RNA. mRNA levels for 
TNFa (A) and LT (B) are expressed as arbitrary units representing integrated 
areas of densitometric tracings obtained by transmission densitometry. Slot blots 
were prepared by loading 8 µg total RNA of sample per slot; autoradiogram 
exposure time was 1 day for TNFa and 3 days for LT. 
In order to determine whether TNF protein levels paralleled the 
observed changes in mRNA, an ELISA method using an antibody which 
recognizes both murine TNFa and LT was used to quantitate TNF protein in 
transplanted cardiac tissues from untreated and low dose CSA/MTX-treated 
recipients. TNF protein levels in cardiac allografts from untreated recipients as a 
group were significantly increased over cardiac allografts in low dose 
CSA/MTX-treated recipients (p .s. 0.001) (Figure 19). TNF protein from untreated 
allografts demonstrated a biphasic pattern, similar to that shown for TNFa and 
LT mRNA from cardiac allograft tissues in untreated recipients. Two and one-
half-fold greater levels of TNF were measured in untreated allografts 
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(approximately 400 pg/ml or 16.5 U /ml; 1 U = approx. 24.3 pg) compared to low 
dose CSA/MTX-treated allografts on day 3 post-tx (p ~ 0.001). A second increase 
in TNF levels appeared in untreated allografts on day 6 post-tx, coincident with 
allograft rejection, as measured by the absence of ECG activity. TNF protein 
levels in cardiac allografts in combination low dose CSA/MTX-treated recipients 
did not vary significantly, measuring approximately 150 pg/ml or 6.0 U /ml at all 
time points examined post-tx (Figure 19). In contrast to TNF protein levels 
measured in cardiac allografts, TNF levels in cardiac isografts were at or below 
standard limits of detection (50 pg/ml) at all times except day 3 (100 pg/ml) 
post-tx (Pizarro et al., 1993a), and were significantly decreased compared with 
time-matched cardiac allografts from either control-untreated (p ~ 0.001) or low 
dose CSA/MTX-treated (p ~ 0.01) recipients. 
Expression of granzymes A and B, HF and Cl1, respectively, were 
examined in cardiac transplants at various times post-tx. Cardiac transplants 
from untreated allograft recipients were analyzed for the presence of HF (Figure 
20A, top panel) and Cl 1 (Figure 20A, middle panel) on days 1 through 8 post-tx 
by Northern blot analysis. Expression of HF and C11 mRNA occurred at later 
time points during the rejection process compared to TNFa and LT. Granzyme 
A and B transcripts were detected on days 5 through 7 and days 5 and 6 post-tx, 
respectively, in cardiac transplants from untreated allograft recipients (Figure 
20A). Granzyme mRNA levels were therefore elevated just prior to allograft 
rejection, with HF and Cl 1 transcript levels undetectable at earlier time points 
post-tx. 
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Fig. 19. TNF protein levels in cardiac transplants from low dose CSA/MTX-
treated and untreated control recipients. Cardiac allograft tissues were retrieved 
on days 1 through 8 post-tx and analyzed for TNF protein, expressed as pg/ ml 
and U/ml (1 U = approx. 24.3 pg)± S.E.M. Data shown are mean values± S.E.M. 
of four experiments performed with different allograft tissue samples (p ~ 0.001). 
Cardiac allografts from combination low dose CSA/MTX-treated 
recipients were also analyzed on days 1 through 8 post-tx by Northern blot 
analysis for HF and Cl 1 mRNA levels. Transcript levels for both HF and Cl 1 
were undetectable in allografts from low dose CSA/MTX-treated recipients on 
all days assayed post-tx (Figure 20B and 20C, respectively). Furthermore, no 
detectable levels of HF or Cll transcripts were found on days 1 through 10 post-
tx in RNA samples prepared from cardiac isografts (Figure 20D). When cardiac 
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allograft samples from untreated and low dose CSA/MTX-treated recipients 
were assayed simultaneously and compared by slot blot analysis, HF (Figure 
21A) and Cll (Figure 21B) mRNA levels were detected only in tissue from 
untreated recipients, at times and levels similar to those demonstrated in 
Northern blot analysis (Figures 20A). 
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Fig. 20A. HF and Cll mRNA levels in cardiac allografts transplanted into 
untreated control recipients. Total RNA isolated from cardiac allografts retrieved 
on days 1-8 post-tx were examined by Northern blot analysis for HF (top panel) 
and Cll (middle panel) gene expression. A representative Northern blot is 
shown above. As with Fig. 20B, 20C, and 20D, blots were prepared using 15 µg 
of total RNA per lane; autogradiogram exposure time was 2 days for both HF 
and Cll probes. Ethidium bromide staining of 18S and 28S ribosomal RNA 
subunits (bottom panel) is included to illustrate uniformity of lane loading and 
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Fig. 20B. HF mRNA levels in cardiac allografts transplanted into low dose 
CSA/MIX-treated recipients. Total RNA isolated from cardiac allografts 
retrieved on days 1-8 post-tx were. examined by Northern blot analysis for HF 
gene expression. Representative Northern blot is shown above. 
Autogradiogram exposure time was 5 days. 
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Fig. 20C. Cl 1 mRNA levels in cardiac allografts transplanted into low dose 
CSA/MTX-treated recipients. Total RNA isolated from cardiac allografts 
retrieved on days 1-8 post-tx were examined by Northern blot analysis for Cll 
gene expression. Representative Northern blot is shown above. Representative 
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Fig. 21. Densitometric measurement of HF and C11 transcript levels from 
representative slot blots of cardiac allograft total cellular RNA. mRNA levels for 
HF (21A) and C11 (21B) are expressed as arbitrary units representing integrated 
areas of densitometric tracings obtained by transmission densitometry. Slot blots 
were prepared by loading 8 µg total RNA of sample per slot; autoradiogram 
exposure time was 3 days for both HF and C11 probes. 
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Fig. 20D. HF and C11 mRNA levels in cardiac isografts transplanted into 
untreated control recipients. Total RNA isolated from cardiac isografts retrieved 
on days 1-7 and 10 post-tx were examined by Northern blot analysis for HF (top 
panel) and Cl 1 (middle panel) gene expression. Representative Northern blots 




Using a heterotopic method of cardiac transplantation into the rat ear, we 
have previously reported that treatment of cardiac transplant recipients with 
combination low dose CSA/MTX immunosuppressive therapy resulted in 
allograft survival times which more than doubled when compared to survival of 
allografts transplanted into untreated control recipients (p ~ 0.01) (Pizarro et al., 
1993b). The average time to rejection of untreated control allografts was 
previously found to be Day 7 post-tx (Pizarro et al., 1993a), whereas combination 
low dose CSA/MTX-treated recipients undergo acute rejection by day 18 post-tx, 
at which time ECG and pulsatile activity was virtually undetectable (Pizarro et 
al., 1993b). In addition, combination low dose CSA/MTX treatment increased 
graft survival over cardiac allografts transplanted in either low dose CSA or MTX 
alone-treated recipients (Pizarro et al., 1993b ). 
In order to elucidate the possible mechanism(s) by which combination low 
dose CSA/MTX prolongs rat cardiac allograft survival, we have previously 
examined IL-2 production at the mRNA level (Pizarro et al., 1993b). IL-2 mRNA 
levels were examined in cardiac allografts to determine if low dose CSA/MTX 
therapy, like high dose CSA treatment, exerted its immunosuppressive action 
through inhibition of IL-2 gene expression. IL-2 appears to be an important 
mediator of allograft rejection since a positive correlation between IL-2 levels and 
rejection episodes has been described (Yoshimura & Kahan, 1985; McKenna et 
al., 1988). CSA is believed to exert its immunosuppressive actions through potent 
inhibition of IL-2 production by T cells (Kronke et al., 1984; Elliot et al., 1984). We 
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found that, in contrast to high dose CSA administration, combination low dose 
CSA/MTX treatment (1.0 mg/kg/day and 450 µg/kg/week, respectively) did 
not alter IL-2 gene expression. Similar patterns of IL-2 gene expression were 
found in cardiac allografts from both low dose CSA/MTX-treated and untreated 
transplant recipients on days 1 through 8 post-tx (Pizarro et al., 1993b). 
Therefore, cardiac allografts in both low dose CSA/MTX-treated and untreated 
control recipients indicated comparable increases in IL-2 mRNA levels. Unlike 
high dose CSA treatment, the mechanism(s) by which low dose CSA/MTX 
combination therapy increases allograft survival time post-tx does not appear to 
be mediated by the inhibition of IL-2 gene expression. 
We, and others, have reported the presence of elevated levels of TNFa and 
LT during allograft rejection (Pizarro et al., 1993a; Lowry & Blais, 1988; Moy & 
Rosenau, 1981). Importantly, results of anti-TNFa and LT antibody therapy 
increasing allograft survival time imply that TNF is a mediator of acute rejection 
(Imagawa et al., 1990b; Scheringa et al., 1991; Teramoto et al., 1991). Taken 
together, these data strongly suggest a role for TNFa and/or LT in the 
pathogenesis of allograft rejection. We therefore chose to investigate the effects 
that combination low dose CSA/MTX therapy might have on the expression of 
these cytotoxic cytokines. 
In the present study, rat cardiac allografts transplanted into combination 
low dose CSA/MTX-treated recipients indicate significant decreases in TNFa 
and LT mRNA and protein levels between days 1 through 8 post-tx when 
compared to untreated allograft controls. Although TNFa transcript levels were 
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significantly decreased in cardiac allografts from CSA/MTX-treated animals, low 
dose CSA/MTX treatment did not abrogate TNFa gene transcription. Low but 
detectable levels of TNFa mRNA were seen on day 3 post-tx, and again on days 7 
or 8 post-tx with combination treatment, similar to the pattern in control 
allografts from untreated recipients. In contrast to TNFa gene expression, LT 
mRNA levels in cardiac allograft transplants from low dose CSA/MTX-treated 
recipients were virtually undetectable on days 1 through 8 post-tx. 
TNF protein levels in cardiac allografts transplanted into untreated 
recipients were significantly increased over cardiac allografts from low dose 
CSA/MTX-treated recipients (p 5. 0.001). TNF protein in allografts from 
untreated recipients demonstrated a biphasic pattern, similar to that shown for 
TNFa and LT mRNA, while TNF protein levels in transplants from low dose 
CSA/MTX-treated recipients remained low and did not significantly fluctuate on 
days 1 through 8 post-tx. In contrast to cardiac allografts transplanted into either 
control or low dose CSA/MTX-treated recipients, TNF protein levels in time-
matched cardiac transplants from isograft recipients have been shown to be at or 
below standard limits of detection on all measured time points except day 3 post-
tx (Pizarro et al., 1993a). Therefore, TNF protein levels in cardiac isografts were 
found to be significantly decreased when compared to cardiac allografts from 
either control or low dose CSA/MTX treated recipients, indicating that TNF 
expression appears to be allograft specific. 
In addition to TNFa and LT levels, expression of granzymes A and B was 
also examined in cardiac transplants. The HF (granzyme A) gene encodes a 
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trypsin-like serine esterase, while Cll (granzyme B) encodes a chymotrypsin-like 
serine protease with apparent specificity for acidic residues (Lobe et al., 1986). 
The HF protein is promptly secreted by both cytotoxic CD4 + and CDS+ T cells 
and NK cells after stimulation in vitro, while Cll has been detected in activated 
cytotoxic T lymphocytes and NK cells (Velotti et al., 1989; Griffiths & Mueller, 
1991a). Granzymes are considered to be essential mediators in cell-mediated 
cytolysis by both cytotoxic T cells and NK cells, and it has been postulated that 
they may serve as diagnostic markers for cardiac allograft rejection (Griffiths et 
al., 1991b ). 
In the present study we report that expression of HF and Cl 1 occurs at 
later times during rejection compared to TNF. Granzyme mRNA levels were 
elevated just prior to allograft rejection, with HF or Cll transcript levels 
undetectable at earlier time points post-tx. Granzyme mRNA levels in cardiac 
allografts from combination low dose CSA/MTX-treated recipients were 
undetectable in low dose CSA/MTX-treated allografts on all days assayed post-
tx. Furthermore, no detectable levels of either HF or Cl 1 transcripts were found 
in day-matched cardiac isografts. Therefore, although granzymes may be 
indicators of rat cardiac allograft rejection, TNFs may serve as important early 
marker of cardiac allograft rejection. 
The present study reports a decreased expression of the cytotoxic 
cytokines TNFa and LT, and granzymes A and B, (HF and Cll), in cardiac 
allografts transplanted into low dose CSA/MTX-treated recipients when 
compared to untreated recipients. The actual functional significance of 
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combination low dose CSA/MTX treatment, however, is less well understood. It 
has been demonstrated that low dose CSA therapy (2.0 mg/kg/ day) of allograft 
recipients reduces T cell proliferative responsiveness, but is unable to sustain 
long-term cardiac allograft survival (Stepkowski et al., 1989). The possibility 
exists that low dose CSA may also affect TNFa production from T lymphocytes 
since activated peripheral T cells have been shown to be a contributing source of 
TNFa (Steffen et al., 1988). In addition, the immunosuppressive effect of low 
dose CSA may not be limited to T lymphocytes; in fact, low dose CSA treatment 
(1.0 µg/ml) has been described to also affect monocyte cell function in vitro by 
inhibiting IL-la and ~, as well as PGE2 production (Reisman et al., 1991). 
However, in vivo, different populations of human monocytes have been reported 
to possess varying sensitivities to CSA (Esa et al., 1988). The possibility therefore 
exists that low dose CSA may affect production of TNF as well as IL-2. 
Low dose CSA therapy, while prolonging cardiac allograft survival, does 
not have the efficacy of combination low dose CSA/MTX. In addition, the 
mechanism(s) by which MTX appears to exert immunosuppression is still poorly 
understood, it is believed that MTX possesses primarily anti-inflammatory 
activity (Weinblatt et al., 1985). Direct evidence of MTX immunomodulation is 
supported by reports describing the effects of MTX in experimental models of 
arthritis, in which the production of IL-1 and induction of primary delayed-type 
hypersensitivity were inhibited in MTX-treated rats (Hu et al., 1988; O'Callaghan 
et al., 1986). 
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The present study explores the mechanism of action of combination low 
dose CSA/MTX therapy in prolonging cardiac allograft survival. The possibility 
exists that low dose CSA/MTX combination therapy may act on two different 
effector cells of the immune response, i.e., cytotoxic T cells and macrophages, by 
inhibiting production of immune mediators, such as granzymes and TNF. The 
present study also supports a role for the cytotoxic cytokines, TNFa and LT, and 
granzymes A and Bin the pathogenesis of allograft rejection. Experiments are 
currently underway in our laboratory to examine levels of these cytotoxic gene 
products just prior to rejection time in combination low dose CSA/MTX treated 
recipients of cardiac allografts. Studies such as these are designed to elucidate 
the pathophysiological mechanisms involved in graft rejection and may lead to 
more effective immunosuppressive therapy using synergistic combination 





One of the major problems associated with cardiac transplantation is 
rejection of the allografted heart. The immune response to alloantigen involves 
the production of, by different cell types, soluble endogenous mediators, which 
include cytokines and granzymes. The present dissertation has investigated 
possible pathophysiological mechanisms involved in cardiac allograft rejection 
by examining the production of these cytotoxic mediators in a heterotopic model 
of rat cardiac transplantation. In particular, detection and quantitation of the 
cytotoxic products TNFa, LT, HF, and Cl1, were measured during the process of 
cardiac allograft rejection. Identification of which cytotoxic mediators are 
present during the course of rejection, and when post-tx, may aid in designing 
more specifically targeted therapies aimed to promote graft success. 
Additionally, success of the allografted heart is critically dependent on the 
availability of powerful immunosuppressive agents that have the ability to 
effectively prolong graft survival and prevent allograft rejection. Currently, 
administration of potent immunosuppressive drugs to transplant recipients not 
only dramatically increases the chances of allograft survival, but also with the 
possibility of decreasing toxic side effects. An alternative approach to reduce 
these side effects associated with high dose immunosuppression utilizes the 
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administration of low dose combination therapies that may act synergistically to 
inhibit alloactivation. Studies contained in this dissertation examined the use of 
a low dose CSA/MTX combination therapy during cardiac transplantation. 
Specifically, low dose CSA/MTX combination therapy was investigated in order 
to determine its ability to prolong rat cardiac allograft survival. In addition, 
modulation of the cytotoxic mediators, TNFa, LT, HF, and Cll, was measured in 
cardiac allografts obtained from low dose CSA/MTX-treated recipients. Studies 
such as these are designed to improve allograft success by administrating 
synergistic combination therapies which prolong graft suvival and minimize the 
number of adverse side effects. 
It has previously been shown that donor MHC-incompatible antigens 
have the ability to precipitate a host allograft rejection response in small animal 
models (McKenzie & Henning, 1977; Lowry et al., 1985a). Therefore, MHC-
incompatibility between transplant donor and recipient has become an 
experimental parameter when investigating allograft rejection. The studies 
contained within this dissertation employed a modification of a heterotopic 
method of cardiac transplantation into the mouse ear, originally described by 
Fulmer et al (1963), and applied it to a rat system as a model of allograft rejection 
using the MHC-mismatched BN or DA donor hearts into Lewis recipients as 
allograft pairs and Lewis donor hearts into Lewis recipients as isograft pairs. 
The heterotopic transplantation of cardiac grafts into the rat ear provides 
many advantages when investigating the processes of allograft rejection. Using 
this method, cardiac graft recipients are subject to minimal trauma compared to 
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those undergoing vascular transplantation techniques, and therefore have an 
increased chance of survival. Furthermore, because of the ease of graft 
placement and subsequent graft retrieval, it is possible to evaluate a large 
number of animals for consistent trends characteristic of graft rejection. 
Additionally, graft success is more conveniently monitored. Visual 
transillumination of the recipients' ears is possible to determine size and 
swelling, patterns of vascularization, and pulsatile activity of the cardiac grafts. 
ECG recordings via direct placement of pin electrodes into the ear pinnae on 
either side of the transplanted heart enables quantitative as well as qualitative 
information when monitoring cardiac graft viability. ECG recordings taken from 
heterotopically transplanted cardiac grafts into rat pinnae allow quantitative 
comparative analyses between experimental groups, which may be problematic 
in vascular-connected transplants due to the possible interference of the 
recipient's own intrinsic heartbeat. In fact, using the heart into ear model, the 
ability to distinguish between graft and recipient heart rate is easily determined. 
Therefore, although a nonvascular method of cardiac transplantation into the rat 
ear pinnae may not exactly parallel events occurring in human transplant 
rejection, this model provides multiple advantages when examining the 
pathogenic events leading to allograft rejection. 
Using the rat heart into ear transplantation model, it was established that 
cardiac allografts, but not isografts, undergo rejection by day 10 post-tx, at which 
time ECG activity is undetectable. Additionally, the average day to rejection of 
rat allografted hearts was determined to be 7 days post-tx, whereas isografted 
hearts demonstrated regular ECG and pulsatile activity up to 18 months post-tx. 
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These results are in accordance with a heterotopic method for accessory cervical 
heart transplantation in rats using the same allograft and isograft pairings, which 
has been subsequently established in our laboratory. Using this transplantation 
method of direct vascular anastomoses, the average day to rejection of 
allografted hearts was determined to be 8 days post-tx, while isografted hearts 
displayed viability for at least one year post-tx (Payne et al., submitted). These 
findings are also consistent with earlier reports by other investigators which 
assessed rat cardiac allograft rejection by cessation of palpable pulsatile activity 
(Tilney et al., 1978; Hancock et al., 1991; Scheringa et al., 1991). Taken together, 
these data suggest that the rat heart into ear graft technique may provide a useful 
model to investigate the mechanisms of allograft rejection in cardiac 
transplantation. 
Detection and quantitation of soluble endogenous mediators produced 
during inflammatory processes in response to alloantigen were measured during 
rat cardiac allograft rejection using the heart into ear model. The studies 
contained within the present dissertation focused on the production of cytotoxic 
mediators, including TNF and granzymes. Specifically, TNF -a and ~ (LT) were 
examined for reasons mentioned earlier (Chapter 1), including their many 
proinflammatory actions which may contribute to allograft rejection responses. 
These effects include potent induction of chemotactic factors causing effector cell 
infiltration, augmentation of class I MHC antigen expression, stimulation of 
platelet activating factor (P AF) promoting ischemia within the graft, and 
induction of macrophage activation (Reviewed in Halloran et al., 1989). In 
addition, it had previously been shown that a strong correlation exists between 
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granzyme gene expression and cytotoxic potential (Gershenfield & Weissman, 
1986; Lobe et al., 1986). In fact, one of the first studies demonstrating their 
importance involved the detection of granzyme-expressing lymphocytes in vivo 
during murine cardiac allograft rejection (Mueller et al., 1988). For these reasons, 
including those previously mentioned (Chapter 1), HF and Cll (granzymes A 
and B) were measured, using the aforementioned heart into ear model, for their 
putative role in the process of rat cardiac allograft rejection. 
TNF and granzyme expression was examined in a window of time 
consisting of days 1 through 8, and in some cases through day 10, post-tx. This 
time frame was established based on the findings that using the rat heart into ear 
graft technique, the average time to rejection of cardiac allografts was 7 days 
post-tx, with no detectable ECG activity measured by day 10 post-tx. In fact, 
both TNFa and LT mRNA and protein levels in cardiac allografts consistently 
demonstrated a biphasic pattern of expression where peak levels were reached 
on day 3 post-tx with a second increase on day 6 or 7 post-tx which subsequently 
decreased through day 10 post-tx. In contrast to TNF expression found in 
allografts, TNFa and LT mRNA transcripts were undetectable in isografts on 
days 1 through 10 post-tx, while TNF protein levels were consistently 
undetectable or significantly reduced when compared to time-matched 
allografts. Therefore, these data indicate that increased expression of TNF 
appears to be allograft-specific and occurs early during rat cardiac allograft 
rejection, possibly serving as an important early indicator of transplant rejection. 
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Compared to TNF, granzyme expression occurred at later time points 
during the rejection process. Granzyme mRNA levels were elevated just prior to 
rejection with HF and Cl 1 transcripts detected on days 5 through 7 and days 5 
and 6 post-tx, respectively, in rat cardiac allografts. Furthermore, no detectable 
levels of HF or Cl 1 transcripts were found on days 1 through 10 post-tx in rat 
cardiac isografts. Taken together, these data suggest that although granzymes 
may be indicators of rat cardiac allograft rejection, TNF may serve as an 
important early marker of cardiac allograft rejection. 
As mentioned earlier, the significance of the early rise in TNF (TNFa and 
LT) levels post-tx is unknown. Although the second increase in TNF expression 
appears to be solely allograft-specific, the first peak is noted in both allograft and 
to a lesser extent, in isograft tissues. Speculation regarding this early elevation in 
TNF gene expression may be, in part, due to postsurgical inflammatory 
(nonallospecific) events. In addition, this significantly greater early TNF 
response present in allografts may reflect allospecific events, including 
endothelial cell activation (Collins et al., 1986) and augmented migration and 
adhesion of leukocytes (Shalaby et al., 1985). Furthermore, since TNF is known to 
have angiogenic properties, the possibility exists that an increase in TNF 
production following transplantation may be due, in part, to the graft's need for 
vascularization. One possible source of TNF may be activated mononuclear 
phagocytes in the heart graft, since it has been reported that TNFa is released by 
infiltrating macrophages which are present early in the rejection process (Lowry 
& Blais, 1988; MacPherson & Christmas, 1984; Payne et al., submitted). Another 
contributing source may be activated peripheral T lymphocytes, which have also 
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been shown to synthesize TNF (Steffen et al., 1988). Therefore, results obtained 
from the present studies indicate significant elevations in graft TNF levels well in 
advance of transplant rejection. 
The second increase in TNF levels observed in cardiac allografts appears 
to coincide with the time of graft rejection. Although the actual roles of TNFa 
and LT in rejection are not clearly defined, they may participate in the rejection 
process by indirect activation of leukocyte subpopulations or by direct lytic 
mechanisms of the graft parenchyma. The biphasic pattern of TNF expression 
demonstrated in the present studies is also consistent with previous reports 
demonstrating that rat cardiac allografts elicit a biphasic cellular immune 
response, with the second phase coinciding with the time of acute graft rejection 
(Tilney et al., 1978). More recent studies also showed similar trends of bimodal 
TNF expression in the pathogenesis of rat lung allograft rejection, with 
significant attenuation in those recipients pretreated with neutralizing TNF 
antisera (DeMeester et al., 1993). Therefore, activated mononuclear leukocytes, 
including macrophages, infiltrating the graft parenchyma may be responsible for 
the early rise in TNF levels which subsequently may serve as an early marker of 
incipient rejection, while the second increase in TNF levels is more coincident 
with graft rejection and may represent an accumulation of events leading to 
eventual tissue graft destruction. 
These data are also supported by recent findings in our laboratory using a 
heterotopic method for accessory cervical heart transplantation, wherein 
immunohistochemical characterization of the cellular phenotypes present in 
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rejecting rat cardiac allografts was performed (Payne et al., submitted). The 
results from these studies demonstrated significantly elevated staining in cardiac 
allografts for the macrophage/monocyte population as early as day 2 post-tx, 
which remained sustained through day 8 post-tx. Moreover, macrophages 
appeared to precede T cells in transplant infiltrates; immunohistologic staining 
for the CDS+ T cell subset was markedly increased by day 4 post-tx and appeared 
to be allograft-specific (Payne et al., submitted). This is consistent with the 
expression of the granzymes, HF and Cll in the present dissertation which was 
present between days 5 through 7 post-tx in cardiac allografts. Therefore, as 
stated earlier, granzymes may indicate rejection, however, TNF appears to be an 
earlier marker of rat cardiac allograft rejection. 
Once the time course for TNF and granzyme elaboration was determined 
in the rat heart into ear transplantation model, it appeared as though the crucial 
window of time for studying TNF and granzyme expression was on days 1 
through 8 post-tx. A low dose CSA/MTX combination immunosuppressive 
therapy was then investigated as a possible approach to prolong allograft 
survival and to examine how this treatment would modulate TNF and granzyme 
expression. As stated earlier, low dose CSA/MTX treatment was considered as 
an alternative immunosuppressive therapy to promote allograft survival while 
minimizing high dose CSA side effects. Furthermore, immunosuppressive 
effects have been attributed to MTX (Mitchell et al., 1969), which has shown some 
success in the treatment of rheumatoid arthritis (Weinblatt et al., 1985; Perhala & 
Wilke, 1991). 
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The results from the present studies have indicated that low dose 
CSA/MTX treatment significantly prolonged rat cardiac allograft survival over 
day-matched allografts transplanted into untreated control recipients, where the 
average day to rejection was day 18 and day 7 post-tx, respectively. Therefore, 
treatment of cardiac allograft recipients with combination low dose CSA/MTX 
therapy more than doubled allograft survival time post-tx when compared to 
untreated controls. Combination low dose CSA/MTX therapy also significantly 
increased graft survival compared to low dose CSA alone as well as MTX-alone 
treated allograft recipients. High dose CSA-treated recipients had the longest 
allograft survival time (36 days); however, high mortality was noted in this 
treatment group following anesthesia administration during cardiac monitoring. 
Although the reasons for this phenomenon are unknown, the possibility exists 
that apparent complications may be due to known toxicities associated with high 
dose CSA administration. 
The mechanism(s) by which low dose CSA/MTX combination therapy 
produces its effect is unknown. Low dose CSA treatment (1.0 mg/kg/day) of 
allograft recipients has been shown to reduce T cell proliferative responsiveness 
but was unable to sustain long-term cardiac graft survival (Stepkowski et al., 
1989). This suggests that low dose CSA has the ability to prolong cardiac graft 
survival post-tx by activation of T cell suppressor function(s) and / or by altering 
T cell proliferation. In fact, the present studies indicate that low dose CSA 
treatment, while able to delay allograft rejection, does not have the efficacy of 
combination low dose CSA/MTX in prolonging rat cardiac allograft survival. 
Therefore, the possibility exists that MTX provides additional 
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immunosuppressive capabilities by affecting T cell function and/ or regulating 
other cells participating in the immune response. 
Although it is unclear by which mechanism(s) MTX exerts its 
immunosuppressive effects, animal studies support an anti-inflammatory mode 
of action. In a murine model of adjuvant-induced arthritis, MTX has been 
reported to inhibit hind paw edema, the activation of macrophages by PGE2, the 
influx of MHC class II and macrophages into synovial tissue, and IL-1 
production (Hu et al., 1988). These data support the possible role MTX may have 
in inhibiting macrophage effector cell function. Therefore, in the present study, 
significant prolongation of cardiac allografts transplanted into combination low 
dose CSA/MTX-treated recipients may be due, in part, to the combined 
immunosuppressive actions of low dose CSA primarily at the T cell level and 
MTX primarily at the macrophages effector cell level. 
IL-2 mRNA levels in transplanted cardiac tissues was also examined to 
determine whether combination low dose CSA/MTX treatment, like high dose 
CSA, exerts its immunosuppressive action by altering steady state levels of IL-2 
mRNA. IL-2 gene transcripts were not detected in isografts or in allografts 
transplanted into high dose CSA-treated recipients on any day post-tx when 
compared to allografts from untreated recipients, supporting previous reports 
demonstrating suppression of IL-2 gene transcription with high dose CSA 
administration (Kronke et al., 1984 and Elliot et al., 1984). No apparent 
differences in IL-2 mRNA transcript levels were observed, however, between 
allografts transplanted into untreated and low dose CSA/MTX-treated 
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recipients. IL-2 mRNA transcripts appeared early after transplant and remained 
elevated through day 8 post-tx. Therefore, unlike high dose CSA therapy, the 
mechanism(s) by which low dose CSA/MTX prolongs allograft survival does not 
appear to be mediated by the inhibition of IL-2 gene transcription. 
The effects of low dose CSA/MTX on the expression of the cytotoxic 
mediators, TNFa, LT, and granzymes A and B (HF and Cll, respectively) were 
then examined in an attempt to elucidate possible mechanism(s) by which low 
dose CSA/MTX therapy increases the time of allograft survival. Significant 
suppression of TNFa, LT, HF, and Cll gene expression was seen on days 1 
through 8 post-tx in cardiac allografts from low dose CSA/MTX-treated 
recipients compared to untreated allograft controls. TNF protein levels in cardiac 
allografts from low dose CSA/MTX-treated recipients were also found to be 
significantly reduced on days 1 through 8 post-tx when compared to time-
matched untreated allograft controls. This data indicate that low dose 
CSA/MTX treatment is effective in prolonging rat cardiac transplant survival 
and appears to act at the transcriptional level to downregulate cytotoxic gene 
expression. Table 4 describes the studies contained within this dissertation by 
summarizing the cytokine and granzyme levels in low dose CSA/MTX-treated 
and untreated control cardiac grafts. Table 4 is a qualitative description 
comparing relative levels of mediators among experimental groups; quantitative 
measurements can not be extrapolated from this information. 
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TABLE 4. Summary of cytokine levels in low dose CSA/MTX-treated and 
untreated control cardiac grafts. 
DAY POST-TX CYTOKINE 
TREATMENT MEASURED 
1 2 3 4 5 6 7 8 
CSA/MTX ++ + + 
TNFa 





ALLO.CONT. ++-I ++ mRNA 
ISO.CONT. 
CSA/MTX + +++ ++ + ++ + + 
TNF 








ALLO.CONT. + + mRNA 
ISO.CONT. 
CSA/MTX + + +++ +++ 4-++ +++ ++-+ ft-+-+ 
IL-2 
ALLO.CONT. + + +++ ++-+ ft-++ +++ ++-+ ft-+-+ mRNA 
ISO.CONT. 
129 
The actual functional significance of combination low dose CSA/MTX 
treatment is less well understood. As mentioned earlier, the possibility exists 
that low dose CSA may affect T cell responsiveness (Stepkowski et al., 1989) as 
well as TNF production from T lymphocytes since activated peripheral T cells 
have also been shown to be a contributing source of TNFa (Steffen et al., 1988). 
In the same manner, CSA may also have an effect on granzyme production since 
granzymes have been shown to be primarily a T cell product. Additionally, as 
stated earlier, the possibility exists that MTX may play a role in downregulating 
macrophage effector cell function. Therefore, TNFa production by macrophages 
may be affected by MTX administration. In the present studies, significant 
prolongation of cardiac allografts transplanted into combination low dose 
CSA/MTX-treated recipients may be due to combined immunosuppressive 
actions of both low dose CSA and MTX, acting on both T cells and macrophage 
effector cells. 
Alternatively, the combination of low dose CSA plus low dose MTX may 
act in a synergistic manner. Further studies are needed to examine the effects of 
both low dose CSA alone and low dose MTX alone treatment on the 
aforementioned cytotoxic mediators in order to determine if a single 
immunosuppressive agent is regulating a specific cytokine or if the combination 
low dose CSA/MTX is acting synergistically. In addition, it would be interesting 
to perform dose-response experiments in which the dose of each individual 
immunosuppressive agent (CSA or MTX) would vary, and their effect on each 
cytotoxic mediator measured. In this way, an ideal dosage of each 
immunosuppressive drug can be established to downregulate a specific cytotoxic 
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mediator. Furthermore, an optimal dosage of combination CSA/MTX which 
elicits the greatest decrease in one or more mediators may be determined. 
The studies contained within this dissertation have explored the 
possibility of using combination low dose immunosuppressive therapy, 
specifically low dose CSA/MTX, as an alternative treatment aimed at prolonging 
rat cardiac graft survival while minimizing adverse side effects often associated 
with use of high dose immunosuppression following allograft transplantation. 
Low dose CSA/MTX combination treatment has been shown to decrease the 
expression of the cytotoxic mediators TNFa, LT, HF, and Cll during allograft 
rejection. Figure 22 summarizes the postulated effects that low dose CSA/MTX 
combination therapy may have on TNF and granzyme production during rat 
cardiac allograft rejection. 
The need remains for CSA, MTX, and other immunosuppressive drugs to 
be evaluated for their efficacy in downregulating TNFa, LT, HF, C11, and other 
proinflammatory mediators involved in allograft rejection. Insight into which 
cytotoxic mediators are synthesized, and when post-tx they appear, may provide 
opportunities for early detection of molecular "markers" that signal impending 
rejection. Assessment of the cytokine profile during allograft rejection may also 
aid in the development of more specifically targeted immunosuppressive 








IIftliB CSA/MTX ACTIONS 
Fig. 22. Postulated effects of low dose CSA/MTX administration on TNF and 
granzyme production during rat cardiac allograft rejection. 
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